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ABSTRACT 
 
 Ascariasis is a neglected tropical disease that is caused by the nematode 
parasite Ascaris. Ascaris infections have high morbidity, cause debilitating conditions 
and affect at least one-quarter of world’s population. With no effective vaccine 
available, the prophylaxis and treatment of ascariasis rely on a limited supply of 
anthelmintic drugs. The massive use of anthelmintics led to the selection of resistant 
parasites, which has incurred anthelmintic resistance in many parasite species. It is 
therefore important to identify new lead compounds for anthelmintic drugs or to 
enhance the potency of existing anthelmintics. To address this issue, I chose a 
recently characterized ligand-gated ion channel, ACR-16 on Ascaris suum, as my 
drug target and attempted to discover new therapeutic compounds targeting at Asu-
ACR-16 receptor. I used two approaches of structure-based drug discovery that are 
arranged into individual chapters in my thesis. In Chapter 2, the receptor-based drug 
design was applied to perform virtual screening of a library of ligands into the 
potential binding sites of receptor structure. The hit candidates were then 
pharmacologically characterized on Asu-ACR-16 expressed in Xenopus laevis 
oocytes using two-electrode voltage clamp. In Chapter 3, the ligand-based drug 
design was applied to optimize the structure of nicotine, a known nAChR agonist, to 
identify more potent and efficacious Asu-ACR-16 agonists. In conclusion, we 
reported four novel allosteric modulators from virtual screening and several (S)-
anabasine derivatives as highly potent Asu-ACR-16 agonists.         
1 
 
CHAPTER I 
 GENERAL INTRODUCTION 
1. Introduction 
1.1 Ascaris: a soil-transmitted helminth  
Parasites are organisms that live on (ectoparasites) or in (endoparasites) the 
host organism and harm the host. Endoparasites, including all parasitic worms, are 
parasites that inhabit in different organs and tissues of the host. Helminths, meaning 
parasitic worms, comprise three main groups: the nemathelminths (roundworms), 
the trematodes (flukes) and the cestodes (tapeworms). Intestinal helminths, namely 
roundworms (Ascaris), whipworms (Trichuris trichiura) and hookworms (Anclostoma 
duodenale and Necator americanus), are transmitted through contaminated soil, and 
thus called soil-transmitted helminths (STHs).  
As a most widespread STH, Ascaris infects approximately 1.4 billion people 
worldwide and is most common in school-aged children (Keiser et al., 2010; Wani et 
al., 2010; Dold et al., 2011). Ascaris transmits its eggs via the feces of infected 
persons. Eggs are deposited and become mature on soil if the feces are used as 
fertilizer. People are infected with Ascaris when they ingest eggs, which then grow 
into adult worms in human intestine. Adult worms feed on nutrients at the expense of 
the host, and can cause intestinal obstruction, malnutrition and iron-deficiency 
anemia (Brooker et al., 2004). Ascariasis occurs mainly in areas with warm and 
moist climates where sanitation and hygiene are poor, including sub-Saharan Africa, 
2 
 
the Central and South Americas, China, India and south-east Asia (Savioli et al., 
2004).   
Ascaris lumbricoides is a human roundworm that infects more than one billion 
people (de Silva et al., 2003a). Ascaris suum, a roundworm that is very similar to the 
human parasite, A. lumbricoides, infects pigs with high prevalence rates. A. suum 
infection reduces porcine feed to gain ratios and causes liver condemnation, which 
incur severe economic losses (Stewart et al., 1988).  
The life cycle of A. suum, starts from eggs that are ingested by the host pig 
(Fig. 1). The one-celled stage eggs are later develops into the infective stages (L2) 
larvae, which are then released from the small intestine of the host during hatching. 
The L2 juveniles after hatching penetrate the intestinal mucosa and enter into the 
portal circulation of the liver within 24 h. The L2 moults into L3 juvenile in liver and 
later enters into the systemic circulation. The larvae traverse from the blood stream 
into the lungs via pulmonary arteries, 4 to 6 days after infection. The larvae 
penetrate the lung tissue to reach pulmonary capillaries and later into alveoli of the 
lung, 2 weeks after infection. The larvae ascend the bronchial tree to reach the 
throat and are swallowed during coughing. The L3 larvae are re-ingested and arrive 
in the small intestine to complete their growth from L3 to L4 and adults. It takes 
about 2-3 months for this cycle to complete from ingestion of eggs to the adult 
worms. The adult worms can reproduce and live 1-2 years in the intestine. Female 
worms reproduce about 200,000 eggs per day, which are then passed in the host 
feces. The contaminated feces are source of infection to other hosts (Dold et al., 
2011).  
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Fig 1. the life cycle of A. suum in the pig (Dold et al., 2011). 
 
1.2 Anthelmintic drugs and resistance 
No vaccines are currently effective against nematode helminthiasis (Hewitson 
et al., 2014). The prophylaxis and treatment of these infections mainly rely on 
chemotherapy. The drugs that are used to control helminthiasis are called 
“anthelmintics”. Regrettably, there are few classes of anthelmintic drugs, classified 
based on similar chemical structure and mode of action.  
Some classic anthelmintic drugs act rapidly and selectively on neuromuscular 
transmission of nematodes. The neurotransmitters, such as acetylcholine (ach), γ-
aminobutyric acid (GABA) and glutamate, are released at the neuromuscular 
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junctions and activate the post synaptic receptors on the somatic muscle (nicotinic 
acetylcholine receptors (nAChRs) or GABA-gated chloride channels) and pharynx 
(nAChRs or glutamate-gated chloride channels (GluCls)). Nicotinic agonists, namely 
levamisole, butamisole, pyrantel, morantel, bephenium, thenium and methyridine, 
are cholinomimetics that act selectively as agonists at synaptic and extra-synaptic 
nAChRs on nematode muscle cells, produce contraction and spastic paralysis 
(Martin, 1997). Paraherqumide is a competitive antagonist of levamisole-sensitive 
nAChRs in nematode body wall and induces flaccid paralysis (Robertson et al., 
2002). Piperazine is a GABA receptor agonist on nematode muscles that increases 
the opening of the muscle membrane Cl- channels, hyperpolarizes the membrane 
potential and causes flaccid paralysis (Martin, 1982). The avermectins, such as 
ivermectin, abamectin and milbemycin, are a group of broad-spectrum macrocyclic 
lactone antibiotic anthelmintics to control nematode parasites in human and livestock. 
The avemectins increase the opening of GluCls and produce paralysis of pharyngeal 
pumping (Campbell et al., 1984).  
Other classic anthelmintics inhibit biochemical pathways. The benzimidazoles, 
such as albendazole and mebendazole, bind selectively to β-tubulin of nematodes 
and inhibit microtubule formation (Lacey, 1990).  
Several modern anthelmintic drugs are recently reported. Emodepside is a 
cyclooctadepsipeptide that potentiates the SLO-1 Ca2+-dependent K+ channels on 
nematode body muscle (Kulke et al., 2014). Tribendimidine is a selective agonist of 
bephenium-sensitive nAChRs and produces muscle depolarization and contraction 
(Robertson et al., 2015).   
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Unfortunately, the wide and intensive use of limited number of anthelmintics 
has selected the nematodes that can survive the treatment in the worm population. 
These nematodes are genetically and physiologically resistant to the anthelmintic 
drugs and remain their resistant genotypes and phenotypes to next generation 
(Prichard, 1994). Anthelmintic resistance has been reported in many animals 
(Kaplan, 2004; Wolstenholme et al., 2004) and raised the concerns for the 
development of resistance in humans (Taman et al., 2014). Resistance to nicotinic 
agonists is associated with changes in structures of target nAChRs in nematodes 
(Lewis et al., 1980). Ivermectin resistance may be caused by alteration of P-
glycoproteins which transport ivermectin (Xu et al., 1998). Benzimidazole resistance 
is attributed to alterations in their high-affinity binding to parasite β-tubulin (Lubega et 
al., 1990). Resistance has reduced the efficacity of many currently used 
anthelmintics and restricted available treatments for helminthiasis. Therefore, it is 
crucial to identify new drug target sites on nematode or develop new therapeutic 
drugs that selectively target nematode receptors to counter the development of 
anthelmintic resistance (Shalaby, 2013). 
1.3 Nicotinic acetylcholine receptors and interactions with agonists 
Ach was first identified as a neurotransmitter in vertebrates in 1920s. Ach was 
isolated from Ascaris and was found to produce muscle contractions on Ascaris in 
1950s (Mellanby, 1955). The activity of choline acetyltransferase was later studied in 
the excitatory motor neuron of Ascaris, which confirmed ach was the excitatory 
neurotransmitter (Johnson et al., 1985). Ach elicited depolarization and increased 
muscle cell conductance of Ascaris (Coloquhoun et al., 1991).  
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There are two main classes of acetylcholine receptors in vertebrates, nicotinic 
and muscarinic. Nicotinic AChRs are ligand-gated ion channels (LGICs) that are 
activated by nicotine, whereas muscarinic AChRs are G-protein coupled receptors 
(GRCRs) that are activated by muscarine. nAChRs present in both neuronal cells 
and non-neuronal cells, and medicate synaptic transmission at the neuromuscular 
junction of vertebrates (Changeux et al., 1998).  
nAChRs are non-selective cation channels that belong to the Cys-loop LGIC 
superfamily, which also includes cation channel: 5-hydroxytryptamine type 3 
receptors (5-HT3Rs), two anion channels: GABA and glycine receptors. The 
common feature of this superfamily is a cys-loop formed by disulphide bonds 
between two cysteines separated by 13 conserved amino acids in the N-terminal 
domain (Lester et al., 2004). nAChRs comprise five subunits arranged around a 
central ion-conducting pore that is permeable to Na+, K+ and sometimes Ca2+ 
depended on the receptor subtypes. Each subunit starts from extracellular N 
terminal, followed by an extracellular immunoglobulin fold (about ten β strands), four 
transmembrane spanning domains (M1, M2, M3, M4), a cytoplasmic domain 
between M3 and M4, ended with extracellular C terminal. M2 helix lines the channel 
pore. Subunits are classified into α-subunit and non-α subunit, depending on the 
appearance of vicinal cysteines on the extracellular domain. The pentameric 
nAChRs are made of two or more α-subunits, and three or less non-α subunits (Fig. 
2). The Asu-ACR-16, the drug target I am working on in this thesis, is made up of 
five α-subunits and thus is a homomeric pentamer which is sensitive to nicotine.  
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Fig 2. Torpedo nAChR at 4 Å resolution (PDB ID: 2BG9), as viewed from the 
synaptic cleft (A) and parallel with the membrane plane (B). The orthosteric ligand-
binding site is highlighted in (A) and the front two subunits are highlighted in (B) (α, 
red; β, green; γ, blue; δ, light blue). In (B), horizontal bars, the membrane; E, 
extracellular; I, intracellular. (Unwin, 2005a) 
 
The vicinal cysteines in loop C are important for agonists and competitive 
antagonists binding to open the channel. The orthosteric ligand-binding site for 
agonists and competitive antagonists to bind in is at the interface of two adjacent 
subunits, which is formed by the loops A, B & C from the principal face (+) of α-
subunit and by the loops D, E & F from the complementary face (-) of non-α subunit 
or α-subunit (Wu et al., 2015). The allosteric ligand-binding site for allosteric 
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modulators or non-competitive ligands to bind in can be predicted from the crystal 
structure of Caenorhabditis elegans GluCls in complex with its allosteric modulator 
(ivermectin) (Hibbs et al., 2011). The allosteric site is thus at the interface region 
between M2(+), M3(+), M1(-) and M2(-) in the transmembrane domain of nAChRs 
(Fig. 3).  
 
Fig 3. Orthosteric ligand-binding and allosteric ligand-binding sites of Cys-loop 
receptors. (A) Closed-up view of the orthosteric ligand-binding site of α4β2 nAChR 
showing the amino acid residues in the loops that participate in its formation. Loops 
A, B and C are provided by the principal subunit and loops D, E and F by the 
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complementary subunit. (B) The X-ray structure of the transmembrane domain of the 
5-HT3 receptor, a nAChR homolog protein. Each subunit of the transmembrane 
domain contributes four helics (M1-4), which approach one another at the 
intracellular membrane surface, creating a tapered central pore. View of the side of 
the transmembrane domain showing a potential binding site for allosteric modulators 
(marked by a red asterisk). The intersubunit allosteric modulatory site is modeled 
based on the crystal structure of ivermectin bound GluCl. The site is located in the 
transmembrane domain between the four transmembrane segments (M1-4). (Wu et 
al., 2015)   
 
Nicotinic agonists target at nAChRs, and typically contain a protonatable 
amine (eg. nicotine and epibatidine) or quaternary ammonium (eg. ach) that makes 
cation-π interaction with five highly conserved aromatic residues from the principal 
subunit (Xiu et al., 2009). Another feature of nicotinic agonists is a hydrogen bond 
acceptor (eg. pyridine N of nicotine and carbonyl O of ach), which is about 4-6 Å 
away from the cationic nitrogen, that make water-mediated hydrogen bonds with the 
carboxyl and amide backbones of two residues from the complementary subunit 
(Fig. 4) (Blum et al., 2010). All the nicotinic full agonists of Asu-ACR-16 share these 
characteristics (Fig. 5).   
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Fig 4. Nicotinic agonist binding interactions suggested by acetylcholine-binding 
protein (AChBP) and key binding site residues. Shown is a structure of AChBP in 
complex with nicotine (PDB ID: 1UW6). Explicit hydrogens are displayed for 
hydrogen bonding groups. Asn (loop E) and Leu (loop E) are conserved in all 
nAChRs but are replaced by Leu and Met respectively in the AChBP structure 
shown. (Van Arnam et al., 2014)    
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Fig 5. Nicotinic agonists that are full agonists of Asu-ACR-16. Cationic nitrogen 
(blue) and hydrogen bond acceptor (red) correspond to the nicotinic pharmacophore. 
 
1.4 Homology modeling and virtual screening 
Though the three-dimensional structure of Asu-ACR-16 has not been 
determined to date, last decade has witnessed discoveries of several pentameric 
LGICs structures that are homologous proteins of Asu-ACR-16. The X-ray structures 
of invertebrate acetylcholine-binding proteins (AChBPs) in complex with different 
ligands were reported since 2001 (Brejc et al., 2001). AChBPs share 20-25% 
sequence identity with the nAChR extracellular domain and thus serve atomic model 
of the nAChR extracellular domain for studying the ligand-receptor interactions. The 
first full-length structure was the Torpedo marmorata nAChR by cryo-electron 
microscopy (cryo-EM) published in 2005 (Unwin, 2005a). Two prokaryotic LGICs, 
which are cation ion channels and show high sequence similarity to the nAChRs, 
were determined three years later (Hilf et al., 2008; Hilf et al., 2009). The crystal 
structure of a eukaryotic LGIC, C. elegans GluCl was determined in 2011, which 
revealed the transmembrane allosteric ligand-binding site for the first time (Hibbs et 
al., 2011). Two mammalian LGICs, the human GAPAAβ3 receptor and the mouse 5-
HT3A receptor were determined in 2014, which gave insight into the signaling 
mechanisms (Hassaine et al., 2014; Miller et al., 2014).  
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These nAChRs homologs sharing high sequence identities (≥30%) with our 
target receptor, Asu-ACR-16 can be used as structural templates to predict Asu-
ACR-16 structure using homology modeling (Cavasotto et al., 2009). The basic 
assumption of homology modeling is that homologous proteins remain evolutionarily 
conserved sequence and three-dimensional structure as well (Kaczanowski et al., 
2009). The homologous proteins similar in sequences usually imply significant 
structural similarity (Marti-Renom et al., 2000). Thus, we can replace the amino 
acids on the homologous structure with those on the target protein, followed by 
optimization of the model geometry to predict the target protein structure.          
With the structural model of Asu-ACR-16 receptor and ligand library, potential 
binding ligands can be found through in silico screening, based on the binding 
affinities calculated from the ligand-receptor interactions (Rester, 2008). AutoDock is 
one of the most popular docking programs to perform virtual screening (Morris et al., 
2009b). One successive application of AutoDock is the discovery of novel binding 
modes of HIV integrase inhibitor by J. Andrew McCammon. This helped the 
pharmaceutical company Merck to design new drug targeting HIV integrase, which 
led to the first clinically-approved HIV integrase inhibitor (raltegravir).  
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1.5 Electrophysiology and its technique: two-electrode voltage clamp 
 
                 
Fig 6. Equivalent circuit (A) representing a membrane ion channel (B). G: conductor, 
Erev: reversal potential, C: capacitor.  
 
Ion channel is a pore-forming membrane protein where ions fast transport 
through by passing down their electrochemical potential gradient (Hille, 2001). For a 
selective channel that is permeable to one type of ion (i), the electrochemical 
potential difference between the interior and exterior of cell is: 
 Δ = - RTln + . 
Where  and  are the electrochemical potentials of ion i inside and outside the 
cell, R is the gas constant (8.314 V C K−1 mol−1), T is the absolute temperature,  
and  are the concentrations of ion i inside and outside the cell,  is the charge of 
ion i, F is Faraday’s constant (9.648 70 x 104 C mol-1). The Nernst or equilibrium 
potential is ln  , whereas the membrane potential is = . The 
Conductor (G)  Capacitor (C)  
A B 
G 
C 
Erev 
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reversal potential is the voltage at which the current changes its direction, in other 
words, there is no net flow of ion i. This happens when the electrical potential 
gradient ( ) balances off the concentration gradient, which makes the reversal 
potential equals the Nernst potential  (Sherman-Gold et al., 1993).       
Conductor is the place where current flow through. In electrophysiology, 
several ion channels in membrane that open simultaneously behave similar to the 
parallel conductors ( ) (Fig. 6). More accurate representation of an ion 
channel is a conductor in series with two additional circuit elements: 1) a switch that 
represents the channel gating, which will be in the conducting position when the gate 
is open, and 2) a battery that represents the reversal potential of the channel ( ). 
The ion channels (conductors) contribute to the ionic current:  
= , where N is the number of channels, each conductance of which 
is .  
The thinness of membrane makes it a good capacitor, which has the ability to 
store charge ( ) when a voltage occurs across the two boundaries ( ). The 
membrane capacitors contribute to the capacitive current: = = , where  is 
the membrane capacitance. 
Hence, the total membrane current is = + . The membrane current 
( ) can be used to study the bioelectrical properties of ion channels ( ), if we 
offset the interference of capacitive current ( ) by keeping the membrane potential 
constant.   
15 
 
 
Fig 7. Simplified electrical scheme of two-electrode voltage clamp. 
 
The two-electrode voltage clamp (TEVC) is an electrophysiological technique 
which was first introduced by Kenneth Cole and George Marmount in 1940s and 
later became a technique for measuring ion flow through cell membrane channels 
( ) and understanding the physiological and pharmacological properties of ion 
channels in various living systems. Two intracellular microelectrodes are used in 
TEVC: a voltage sensing electrode ( ) and a current injecting electrode ( ). The 
general principle of TEVC is to clamp the membrane voltage at a desired value 
( ), meanwhile measure the transmembrane current ( ) required in 
maintaining the voltage (Fig. 7) (Finkel et al., 1985). Xenopus laevis oocytes are 
widely used expression systems for cloned ion channels. The expressed ion 
channels then can be characterized as potential target for drug treatment by using 
TEVC or whole-cell patch clamp. TEVC recording of Xenopus oocytes provides 
information of current-voltage relationships, kinetics and response of ion channels to 
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different drugs under different physiological conditions (Robertson et al., 2008). In 
this thesis, I used TEVC to characterize and validate the pharmacological activities 
of ligands selected from virtual screening toward the drug target, Asu-ACR-16.    
2. Thesis Organization 
Chapter 1 gives the general background introduction of the need to identify 
new lead compounds as anthelmintic drugs to counter the increasing anthelmintic 
resistance globally. The structural and functional information of the drug target, Asu-
ACR-16 are described in detailed. The general principals of computational biology 
and electrophysiology used in this thesis are also discussed.  
Chapter 2 is a manuscript published in International Journal for Parasitology: 
Drugs and Drug Resistance in 2016. Four novel allosteric modulators of Asu-ACR-
16 were identified from virtual screening based on the structural models of drug 
target. The electrophysiological studies were performed to validate the 
pharmacological activities of these modulators.  
Chapter 3 is a manuscript in preparation for a peer-review journal. Nicotine is 
a potent agonist of nAChRs. I investigated several nicotine derivatives as Asu-ACR-
16 agonists using electrophysiological techniques. With the help of synthetic 
chemistry, the nicotinic pharmacophore was optimized to enhance the potency and 
efficacity of Asu-ACR-16 agonists.   
Chapter 4 presents the general conclusion and future studies in this area. 
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CHAPTER 2 
THE ASCARIS SUUM NICOTINIC RECEPTOR, ACR-16, AS A DRUG TARGET: 
FOUR NOVEL NEGATIVE ALLOSTERIC MODULATORS FROM VIRTUAL 
SCREENING 
A manuscript published in International Journal for Parasitology: Drugs and Drug 
Resistance 6(1): 60-73. 
Fudan Zheng1, Alan P. Robertson2, Melanie Abongwa2, Edward W. Yu1, 3, Richard J. 
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Abstract 
Soil-transmitted helminths infections in humans and livestock cause 
significant debility, reduced productivity and economic losses globally. There are a 
limited number of effective anthelmintic drugs available for treating helminths 
infections, and their frequent use has led to the development of resistance in many 
parasite species. There is an urgent need for novel therapeutic drugs for treating 
these parasites. We have chosen the ACR-16 nicotinic acetylcholine receptor of 
Ascaris suum (Asu-ACR-16), as a drug target and have developed three-
dimensional models of this transmembrane protein receptor to facilitate the search 
for new bioactive compounds. Using the human α7 nAChR chimeras and Torpedo 
marmorata nAChR for homology modeling, we defined orthosteric and allosteric 
binding sites on Asu-ACR-16 receptor for virtual screening. We identified four 
ligands that bind to sites on Asu-ACR-16 and tested their activity using 
electrophysiological recording from Asu-ACR-16 receptors expressed in Xenopus 
oocytes. The four ligands were acetylcholine inhibitors (SB-277011-A, IC50, 3.12 ± 
1.29 µM; (+)-butaclamol Cl, IC50, 9.85 ± 2.37 µM; fmoc-1, IC50, 10.00 ± 1.38 µM; 
fmoc-2, IC50, 16.67 ± 1.95 µM) that behaved like negative allosteric modulators. Our 
work illustrates a structure-based in silico screening method for seeking anthelmintic 
hits, which can then be tested electrophysiologically for further characterization.  
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Keywords 
Asu-ACR-16; Structure-based drug discovery; Homology modeling; Orthosteric site; 
Allosteric modulator; Xenopus expression 
Abbreviations 
ECD, extracellular domain; TID, transmembrane and intracellular domain; (+), 
principal subunit; (-), complementary subunit; NAM, negative allosteric modulator; 
nAChR, nicotinic acetylcholine receptor; AChBP, acetylcholine-binding protein 
1. Introduction 
Soil-transmitted gastrointestinal nematodes, namely roundworms, whipworms 
and hookworms, infect approximately two billion people worldwide and pose a 
significant health challenge to humans and animals (de Silva et al., 2003b; Bethony 
et al., 2006). The infections with the soil-transmitted helminths can cause 
malnutrition, iron-deficiency anemia and impaired cognitive performance (Crompton, 
2000; Hotez et al., 2007). Currently, there are no effective vaccines available 
(Hewitson et al., 2014), and sanitation is not adequate in many countries. The World 
Health Organization (WHO) recommends four anthelmintics for treatment and 
prophylaxis of soil-transmitted nematode infections: albendazole, mebendazole, 
levamisole and pyrantel (Keiser et al., 2008). The repeated use of a limited number 
of anthelmintic drugs has led to an increase in drug resistance in animals and there 
are similar concerns for humans. It is therefore important to identify novel 
therapeutic compounds that selectively target receptors of parasitic nematodes so 
that we maintain effective therapeutics.  
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The nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated 
ion channels that mediate synaptic transmission at neuromuscular junctions of 
vertebrates and invertebrates (Changeux et al., 1998). The neurotransmitter, 
acetylcholine, activates nAChRs by binding to orthosteric binding sites on the 
extracellular domain of the receptor and triggers the opening of the channel pore in 
the transmembrane domain. The opening of the nicotinic receptors leads to an influx 
of sodium and calcium depending on the receptor subtypes, as well as an output of 
potassium ions, followed by membrane depolarization and muscle contraction.   
Nicotinic anthelmintics are selective agonists of nematode muscle nAChRs 
which cause spastic paralysis of the parasites (Martin et al., 2010). There are three 
different pharmacological subtypes of nAChRs present on muscle of Ascaris suum. 
The anthelmintics, levamisole and pyrantel are selective agonists of L-subtypes of 
nAChRs in A. suum (Martin et al., 2012). Bephenium selectively activates B-
subtypes of nAChRs. Nicotine and oxantel selectively activate N-subtypes of 
nAChRs in A. suum (Qian et al., 2006). The anthelmintic monepantel activates 
nAChRs which are composed of DEG-3-like subunits (Haemonchus contortus 
MPTL-1, Caenorhabditis elegans ACR-20 and H. contortus ACR-23 subunits; 
(Rufener et al., 2010; Buxton et al., 2014). We have selected the N-subtype of 
nAChR that is composed of ACR-16 subunits (Ballivet et al., 1996; Polli et al., 2015) 
for a drug target, because it is pharmacologically different to the other nicotinic 
receptor subtypes (Raymond et al., 2000), for further study. Asu-ACR-16 transcript 
has been found in the A. suum muscle and may be involved in locomotion. 
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The ACR-16 nicotinic acetylcholine receptor of A. suum (Asu-ACR-16) is a 
homomeric receptor made up of five identical α subunits. Homomeric nAChRs have 
five identical orthosteric binding sites where agonists and competitive antagonists 
bind at the interface of two adjacent subunits. The orthosteric site is in the 
extracellular domain and is formed by the loops A, B & C of the principal subunit and 
by the loops D, E & F on the complementary subunit (Galzi et al., 1991; Arias, 
2000b). In addition, three allosteric binding sites close to the orthosteric binding sites 
in the extracellular domain have been observed in the α7 nAChR-AChBP chimera 
(Spurny et al., 2015). In the transmembrane domain, an intrasubunit allosteric 
binding site was found in Rattus norvegicus α7 nAChR (Young et al., 2008), while an 
intersubunit allosteric binding site has been found in C. elegans glutamate-gated 
chloride channel (GluCl) (Young et al., 2008; Hibbs et al., 2011; Spurny et al., 2015). 
These well-studied binding sites in nAChRs or other Cys-loop receptors provided our 
framework for characterizing putative orthosteric and allosteric sites in Asu-ACR-16.    
Because of the lack of a crystal structure for Asu-ACR-16, we used homology 
modeling to predict the protein structure, based on the observations that proteins 
with similar sequences usually have similar structures (Cavasotto et al., 2009). In 
this study, we used homology modeling to predict the three-dimensional structure of 
Asu-ACR-16, based on the observed experimental structures of the human α7 
nAChR chimeras and the Torpedo marmorata nAChR as templates. Virtual 
screening was performed for the ACR-16 orthosteric binding sites, using the 
predicted structure to identify the potential candidates of agonists and competitive 
antagonists. Allosteric binding sites were also used to examine the binding 
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properties of virtual screening hits. Subsequently, we tested the pharmacological 
profiles of virtual screening hits on Asu-ACR-16 receptors expressed in Xenopus 
laevis oocytes, using a two-electrode voltage clamp to test the activity of the hits on 
the receptors.   
2. Materials and methods 
2.1 Identification of template structures 
We selected the extracellular domain of Asu-ACR-16 (ECD-Asu-ACR-16) 
because it forms a homologomer that allows homology modeling. In addition, many 
of the agonists that activate Asu-ACR-16, acetylcholine, nicotine, cytisine, 
epibatidine (Abongwa et al., under review), are also known to bind to the orthosteric 
binding sites of extracellular domain of Lymnaea stagnalis AChBP or Aplysia 
california AChBP (Celie et al., 2004; Li et al., 2011b; Rucktooa et al., 2012; Olsen et 
al., 2014a). In addition to the orthosteric binding site, three separate allosteric 
binding sites in the extracellular domain of α7 nAChR are now recognized (Bertrand 
et al., 2008; Pan et al., 2012; Spurny et al., 2015), increasing the possibility of 
identifying allosteric modulators.  
The amino acid sequence of Asu-ACR-16 (Fig. 1) was obtained from the 
UniProtKB/SwissProt database with the accession number F1KYJ9 (Wang et al., 
2011). Structural templates were identified by using BLASTP on NCBI network 
service (Altschul et al., 1997) and PSI-BLAST on the ProtMod server (Rychlewski et 
al., 2000) by searching in the Protein Data Bank (Berman et al., 2000). Three crystal 
structures of human α7 nAChR chimeras with different co-crystal ligands in 
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orthosteric binding site were used: epibatidine bound (PDB code: 3SQ6; (Li et al., 
2011b), no ligand (PDB code: 3SQ9; (Li et al., 2011b), and α-bungarotoxin bound 
(PDB code: 4HQP; (Huang et al., 2013). These structures were selected as the 
templates for three different bound-forms of the ECD-Asu-ACR-16. The three 
models were: the agonist-bound form ECD-Asu-ACR-16; the apo form ECD-Asu-
ACR-16 and; the antagonist-bound form ECD-Asu-ACR-16 (Fig. 2A).  
We modeled the transmembrane and intracellular domains of Asu-ACR-16 
(TID-Asu-ACR-16, Fig. 2B) because of the presence of an intrasubunit allosteric 
binding site that is found in α7 nAChR and an intersubunit allosteric binding site that 
is demonstrated in a Cys-loop receptor, GluCl crystal structure in complex with 
ivermectin (Bertrand et al., 2008; Young et al., 2008; Hibbs et al., 2011). Ivermectin 
is a known allosteric modulator of α7 nAChRs (Krause et al., 1998). The T. 
marmorata nAChR (PDB code: 2BG9 chain A; (Unwin, 2005b) is the only 
pentameric nAChR structure with the transmembrane domains and partial 
intracellular domains determined. Therefore, the transmembrane and intracellular 
domains of T. marmorata nAChR (TID-Tma-nAChR) were selected as the template 
for our TID-Asu-ACR-16 model. 
The sequence of the ECD-Asu-ACR-16 and the human α7 nAChR chimera 
(SwissProt ID: P36544; (Peng et al., 1994) were aligned using CLUSTALW multiple 
alignment (Thompson et al., 1994). The sequence of the TID-Asu-ACR-16 and TID-
Tma-nAChR (SwissProt ID: P02711; (Devillers-Thiery et al., 1983; Devillers-Thiery 
et al., 1984) were aligned using CLUSTALW.  
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2.2 Homology modeling of Asu-ACR-16 
We used Modeller (Eswar et al., 2007) to build a three-dimensional model of 
ECD-Asu-ACR-16 and used JACKAL 
(http://wiki.c2b2.columbia.edu/honiglab_public/index.php/Software:Jackal) to build 
the model of TID-Asu-ACR-16 for each of the five subunits. These five subunits were 
then assembled to generate the pentamer using COOT software (Emsley et al., 
2004). The model geometry was first refined manually, and then optimized by 
PHENIX software (Adams et al., 2010). Each of the TID-Asu-ACR-16 subunits were 
then merged into the ECD-Asu-ACR-16 model by using COOT to edit and alter the 
Cα coordinates of residues around the outer membrane regions. The final optimized 
pentameric model was then visualized using the program PyMol (The PyMOL 
Molecular Graphics System, Version 1.7.4, Schrödinger, and LLC., Fig. 2C & S1). 
2.3 Structure-based virtual screening 
Smiles strings of ligands were downloaded from the lead-like subset of 
commercially available compounds in the ZINC Database (Irwin et al., 2012)  and 
were converted initially to PDB formats using the PHENIX-eLBOW program 
(Moriarty et al., 2009). The ligand and receptor input files were then prepared in 
PDBQT format for AutoDock Vina by using the AutoDock Tools package (Morris et 
al., 2009a). For initial screening, a docking area was defined visually around the 
orthosteric binding site of ECD-Asu-ACR-16 (Fig. 2D S2A & S2B) by a grid box of 40 
Å × 40 Å × 40 Å using 0.375 Å grid point spacing in AutoGrid. The conformations of 
ligands in the binding sites of the receptor were searched with GALS (Genetic 
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Algorithm with Local Search; (Morris et al., 1998). The binding free energies 
between the ligands and receptor were calculated by the combination of the 
knowledge-based and empirical scoring function in AutoDock Vina (Trott et al., 
2010). The best nine binding modes of ligand based on the binding affinities towards 
the three bound-forms of ECD-Asu-ACR-16 models were implemented by AutoDock 
20 runs for each ligand. Each docked ligand was then ranked by its highest binding 
affinity to the orthosteric binding site of the apo, agonist-bound, or antagonist-bound 
model. From the 60,000 screened molecules, we selected the top 9 ligands 
(0.015%) with the highest predicted affinities that had appropriate binding modes 
within the ligand-binding pockets for further study.  We rejected those compounds 
without a cationic nitrogen in their structure and that were known to be: acutely toxic, 
or carcinogenic, or respiratory depressants, caused dermatitis or conjunctivitis or to 
be significant environmental hazards as recorded on the compound Safety Data 
Sheets available from Sigma Aldrich (http://www.sigmaaldrich.com/safety-
center.html). 
The four virtual screen hits (Table 1) out of the top 9 selected ligands (44%) 
were then specifically docked into five allosteric binding pockets: the agonist sub-
pocket (Fig. S2C & S2D); the vestibule pocket (Fig. S2E & S2F) and; the top pocket 
(Fig. S2G & S2H); the intersubunit and; the intrasubunit transmembrane sites (Fig. 
2E S2I S2J). The docking area was defined visually around each allosteric binding 
pockets of Asu-ACR-16 by a grid box of 40 Å × 40 Å × 40 Å using 0.375 Å grid point 
spacing in AutoGrid. The docking was performed by AutoDock Vina (Fig. 3).  
2.4 In vitro synthesis of cRNA and microinjection into Xenopus laevis oocytes 
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We used TRIzol (Invitrogen™) to extract the total RNA samples from a 1 cm 
muscle flap and dissected the whole pharynx of A. suum. The first-strand of cDNA 
was synthesized with oligo RACER primer, Random Hexamer and superscript III 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) from total RNA in the muscle 
and pharynx by reverse transcription polymerase chain reaction (RT-PCR). Full-
length Asu-acr-16 cDNA was amplified with the forward primer 
TTGATGTAGTGGCGTCGTGT, ATCACGCATTACGGTTGATG and the reverse 
primer GCATTGATGTTCCCTCACCT, ATTAGCGTCCCAAGTGGTTG (Boulin et al., 
2011). The XhoI and ApaI restriction enzymes were used to digest the amplified 
product, which was then cloned into pTB207 expression vector (Boulin et al., 2008) 
and linearized by NheI. We used the mMessage mMachine T7 kit (Ambion) to in 
vitro transcribe the linearized cDNA to cRNA, which was then precipitated with 
lithium chloride, re-suspended in RNase-free water, aliquoted and stored at -80 °C. 
The ancillary protein RIC-3 is required for the expression of ACR-16 in 
Xenopus oocytes (Halevi et al., 2003). A 50 nL cRNA mixture was prepared with 25 
ng Asu-acr-16 cRNA, 5 ng Asu-ric-3 cRNA (SwissProt ID: F1L1D9; (Wang et al., 
2011) dissolved in RNAse-free water. The nanoject II microinjector (Drummond 
Scientific, PA, USA) was used to inject the cRNA mixture into the animal pole of the 
de-folliculated X. laevis oocyte (Ecocyte Bioscience, Austin, TX, USA). The injected 
oocytes were separated into 96-well culture plates and incubated in the incubation 
solution (pH 7.5), which is composed of 100 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2·2H2O, 1 mM MgCl2·6H2O, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL 
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penicillin, 100 µg/mL streptomycin and changed daily. The injected oocytes were 
stored at 19 °C for 4-8 days to allow the receptor to be expressed.  
2.5 Two-electrode voltage-clamp oocyte recording 
We used two-electrode voltage-clamp electrophysiology to record the inward 
current generated by the activated Asu-ACR-16 receptors expressed in X. laevis 
oocytes. 100 µM BAPTA-AM (final concentration) was added into the oocyte 
incubation solution 4 h prior to recording, to prevent the current produced by the 
endogenous calcium-activated chloride channels during recording. An Axoclamp 2B 
amplifier (Molecular Devices, CA, USA) was used for recording and oocytes were 
held at -60 mV. A PC computer with software Clampex 9.2 (Molecular Devices, CA, 
USA) was used to acquire the recording data. The microelectrodes used to measure 
current in oocytes were pulled on a Flaming/Brown horizontal electrode puller 
(Model P-97, Sutter Instruments), filled with 3 M KCl and had resistances of 20-30 
MΩ. The microelectrode tips were broken back carefully with Kimwipes (Wilmington, 
NC, USA) to reduce the resistance to 2-5 MΩ. The recording solution was: 100 mM 
NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O and 5 mM HEPES, pH 7.3 (Buxton et al., 
2014). Oocytes were placed into a tiny groove of the narrow oocyte recording 
chamber. The Digidata 1322A (Molecular Devices, CA, USA) was used to control 
the switches that controlled the perfusion of the chamber at a speed of 4-6 ml/min.    
100 µM acetylcholine was applied initially for 10 s as a control to check the 
viability of the oocytes and Asu-ACR-16 expression for all the recordings. Recording 
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solution was then used to wash out the drug from the oocytes for 2-3 min before 
next application of drug perfusion. 
2.6 Drugs 
Table 1 lists the compounds used, their chemical properties and structures. 
Fmoc-4-(naphthalen-2-yl)-piperidine-4-carboxylic acid (fmoc-2), SB-277011-A 
hydrochloride hydrate (SB-277011-A), fmoc-4-(naphthalen-1-yl)-piperidine-4-
carboxylic acid (fmoc-1) and (+)-butaclamol hydrochloride ((+)-butaclamol Cl), 
acetylcholine chloride (ach), methyllycaconitine citrate salt (mla) were purchased 
from Sigma-Aldrich (St Louis, MO, USA). Levamisole hydrochloride (levamisole) was 
purchased from MP Biomedicals (Santa Ana, CA, USA). With the exception of ach 
and mla which were dissolved in the recording solution, the rest of chemicals were 
dissolved in dimethyl sulfoxide (DMSO) to make stock solutions. Stock solutions of 
100 mM were prepared, except for SB-277011-A where a stock solution of 10 mM 
was prepared due to the solubility; stock solutions were frozen until required. 
Working solutions were then prepared by dilution on the day of the experiment.   
2.7 Pharmacological characterization of molecules selected by virtual 
screening 
To characterize the four hits (Table 1) selected by our virtual screening, each 
drug was applied for 10 s to the oocytes expressing Asu-ACR-16 to test if the drugs 
were agonists. They were then tested as antagonists against ach.  
To characterize the antagonistic properties of the four hits, the following 
protocol was used: a) 10 s of 100 µM ach alone; b) then 10 s of 100 µM ach + hit 
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and then; c) 10 s of 100 µM ach alone. This test procedure was repeated with 
increasing concentrations of the four hits (Fig. 4A-4D), to determine the inhibitory 
dose-response relationships and IC50 by fitting Hill equations to the inhibitory dose-
response curves using GraphPad Prism 5.0 (Graphpad Software Inc., CA, USA).  As 
a further study of the antagonism, each of the four hits was applied before and 
during 10 s test applications of increasing concentrations of ach (Fig. S4).  
2.8 Data analysis 
The data from electrophysiological recordings were analyzed using Clampfit 
9.2 (Molecular Devices, CA, USA) and GraphPad Prism 5.0 (Graphpad Software 
Inc., CA, USA). In all recordings, the peak currents in response to applied drugs 
were measured, which were later normalized to the control 100 µM ach response, 
and expressed as mean ± S.E.M. The mean % inhibition of currents elicited by 100 
µM ach ± S.E.M. was used to determine the inhibition percentage, which was 
quantified using the following equation:  
 
Inhibition (%) =     
where Imax control was the peak current of the control 30 s application of 100 µM ach, 
Imax was the peak current of the 100 µM ach that preceded the 10 s co-application of 
ach and antagonist. Iant was the minimal current during the co-application of 100 µM 
ach and antagonist. Iant control was the current at the same point from the beginning of 
the 30 s application as Iant during the control 30 s application of 100 µM ach (Fig. 
4E). Concentration-response relationships or concentration-inhibition (%) 
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relationships were analyzed by fitting data points into the Hill equation, with at least 
four replicates of each experiment set. 
2.9 Drug treatment of C. elegans 
The wild-type C. elegans strain N2 were obtained from the Caenorhabditis 
Genetics Center (University of Minnesota, MN, USA). We grew C. elegans at 20 °C 
on nematode growth media (NGM, 3 g/l NaCl, 17 g/l agar, 2.5 g/l peptone, 1 mM 
CaCl2, 5 mg/l cholesterol, 1 mM MgSO4, 25 mM KPO4 buffer) agar plates, seeded 
with Escherichia coli OP50 lawn under standard conditions (Brenner, 1974). Ten 
larvae at L4 stage with active thrashing movement (defined as “normal”) were 
transferred from NGM plates into M9 buffer (3 g/l KH2PO4, 6 g/l Na2HPO4, 5 g/l 
NaCl, 1 mM MgSO4) in 24-wall plates for each treatment. We counted the number of 
worms with normal motility in M9 buffer with diluted drugs from the stock solutions 
(≤1% DMSO) at 0, 5, 10, 15 and 20 min. Five replicates were applied for each 
treatment. Motility between negative control (1% DMSO, final concentration) and 
drug treated worms were compared at each time point using student t-test.  
3. Results 
3.1 Sequence alignment of Asu-ACR-16 and template homologue proteins 
The full-length protein sequence of Asu-ACR-16 (504 residues) was retrieved 
from the SwissProt database, of which the ECD-Asu-ACR-16 accounts for 234 
residues. The first 25 resides of Asu-ACR-16 were excluded from alignment with the 
full length human nAChR α7 chimera (204 residues) because of the shorter length of 
the template protein sequence. The human α7 nAChR chimera shows 37.6% 
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sequence identity and 72.9% sequence similarity with the ECD-Asu-ACR-16, based 
on the alignment generated by CLUSTALW (Fig. 1A, job ID: 65782ad6ad6d). The 
TID-Tma-nAChR subunit A shows 22.0% sequence identity and 45.4% sequence 
similarity with TID-Asu-ACR-16, aligned by CLUSTALW (Fig. 1B, job ID: 
644888f4f30e). The residues involved in the putative orthosteric and the allosteric 
binding sites are highlighted in amino acids sequence of Asu-ACR-16. 
3.2 Models of the Asu-ACR-16 pentamer 
The model of the antagonist-bound form of the ECD-Asu-ACR-16 subunit 
starts from an N-terminal α helix followed by seven β strands that comprise an 
immunoglobulin fold. Loop A (Val114 – Ala122), loop B (Lys169 – Lys179), loop C 
(Phe213 – Pro220) from the principal subunit, and loop D (Ala78 – Ala83), loop E 
(Ile143 – Pro144), loop F (Gly185 – Met204) from the complementary subunit are 
involved in forming the orthosteric binding site. A disulphide bond between Cys152 
and Cys166 forms the characteristic component of Cys-loop receptors. The C-
terminal continues into the transmembrane domain (Fig. S1A).  
The transmembrane domains of the Asu-ACR-16 model are made of four α-
helices (M1, M2, M3 and M4). M1 links to the β7 sheet of the extracellular domain 
and extends down into the membrane and is followed by the M2 and the M3 helixes 
as the membrane-spanning portions. The MA cytoplasmic loop (helix) connects 
between M3 and M4. The region between M3 and MA is not modeled due to the 
poorly defined intracellular domain of the template structure. The C-terminal follows 
the M4 helix and faces toward the extracellular surface (Fig. S1B).  
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The pentameric model of Asu-ACR-16 has a five-fold symmetric around the 
channel pore. The average pairwise Root Mean Square Deviation (RMSD) fit of the 
Cα coordinates of the antagonist-bound ECD-Asu-ACR-16 pentameric model and 
human α7 nAChR chimera pentamer (PDB code: 4HQP) was 0.9 Å, which indicates 
a strong structural conservation between the model and the template structures (Fig. 
S1C). The Cα-RMSD between the TID-Asu-ACR-16 pentamer and the TID-Tma-
AChR pentamer was 1.5 Å, which shows the TID fit is still good but not as good as 
the ECD fit. The membrane-spanning domains are arranged symmetrically. The M2 
helix lines the channel pore, while M1, M3 and M4 do not contribute to the channel 
pore and are arranged peripherally (Fig. S1D). 
Since no binding sites data of Asu-ACR-16 is available to date, we used the 
published orthosteric binding site and allosteric binding sites in nAChRs or other 
Cys-loop receptors to predict the putative binding sites in Asu-ACR-16 (Galzi et al., 
1991; Arias, 2000b; Young et al., 2008; Hibbs et al., 2011; Spurny et al., 2015). The 
orthosteric binding site is at the interface between the principal site and the 
complementary site in two adjacent subunits of the ECD-Asu-ACR-16 pentamer 
(Fig. 2 S2A & S2B). The principal subunit (+) has vicinal cysteines (Cys216, Cys217) 
that makes up of the loop C of the binding site. The complementary subunit (-) does 
not use vicinal cysteines as part of the binding pocket and the residues are more 
variable when nAChRs are compared. The agonist sub-pocket, which we argue is a 
less significant allosteric binding site in ECD-Asu-ACR-16, is located right below the 
orthosteric binding site in the extracellular domain (Fig. 2 S2C & S2D). The vestibule 
pocket (Fig. S2E & S2F) and the top pocket (Fig. S2G & S2H) were not high affinity 
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binding sites for the ligands and are not discussed further in this manuscript. The 
intersubunit allosteric binding sites in TID-Asu-ACR-16 are at the interface region 
between M2(+), M3(+), M1(-) and M2(-) (Fig. 2 S2I & S2J). The intrasubunit 
allosteric binding sites are at the center of the four transmembrane helixes (M1, M2, 
M3 and M4) in each of the five subunits.  
3.3 Binding properties of virtual screening hits 
We carried out virtual screening of the ZINC ligand-database by using the 
three different bound forms of the ECD-Asu-ACR-16 models. Four molecules were 
selected as hits based on their high binding affinities and appropriate binding modes 
within the ligand-binding sites. The 9-fluorenylmethoxycarbonyl group (FMOC) was 
observed in twelve out of top forty hits ranked by binding affinities and exists in the 
two out of four hits, which suggests that FMOC could be necessary for the ligand 
recognition by the receptor. The FMOC group has a low predicted bioavailability due 
to the biphenyl scaffold, which limits aqueous solubility and may affect distribution to 
the A. suum parasite. Table 1 lists the physicochemical characteristics of four hits. 
They have relatively high molecular weights and are more hydrophobic compared to 
known Asu-ACR-16 agonists. However, they do follow the Lipinski’s rule of five, 
which suggests that these molecules may be orally actively (Lipinski et al., 2001; 
Lipinski, 2004).  
The atomic structure predicts the partition-coefficients (XlogP) of the four hits 
to be between 4.27 and 6.04 (Table 1). The XlogPs suggest that the four hits are 
10,000-1,000,000 times more concentrated in the lipophilic phase of the lipid bilayer 
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than the aqueous phase of the extracellular domain (Cheng et al., 2007). The four 
hydrophobic hits are, therefore, more likely to bind into the transmembrane allosteric 
binding pockets rather than to the extracellular ligand binding sites. The four hits 
which bind in the transmembrane allosteric binding pockets are therefore predicted 
to be allosteric modulators of the Asu-ACR-16 receptor that alter the activity of the 
agonists or competitive antagonists that bind to orthosteric binding site. SB-277011-
A is known to be a potent and selective dopamine D3 receptor antagonist with high 
oral availability (Stemp et al., 2000). (+)-butaclamol Cl is a non-selective dopamine 
receptor antagonist and a potent antipsychotic agent (Chrzanowski et al., 1985). No 
paper reporting on the activities of fmoc-2 and fmoc-1 has been published to date.  
The four hits (Table 1) were tested for docking into the orthosteric binding 
sites of the three forms of ECD-Asu-ACR-16 models and the five allosteric binding 
pockets in the antagonist-bound form of full-length Asu-ACR-16 models. All four hits 
bound to the orthosteric binding sites of three ECD-Asu-ACR-16 models, but only 
bound to the three allosteric binding sites out of five: intersubunit and intrasubunit 
transmembrane pockets and agonist sub-pocket (Fig. 3) with high binding affinities.  
In the intersubunit transmembrane site of TID-Asu-ACR-16 model, M243 (M1, 
(-)), L247 (M1, (-)) make hydrophobic interactions with naphthalene of fmoc-2. T312 
(M3, (+)), S284 (M2, (+)) form hydrogen bond with carboxylic acids of fmoc-2. F279 
(M2, (-)), I282 (M2, (-)) make hydrophobic contacts with fluorene of fmoc-2. F279 
(M2, (-)), P244 (M1, (-)) make hydrophobic interactions with tetrahydroisoquinoline of 
SB-277011-A. N240 (M1, (-)) forms a hydrogen bond with carboxamide of SB-
277011-A. P288 (M2, (+)) has hydrophobic interaction with quinoline of SB-277011-
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A. L247 (M1, (-)), F279 (M2, (-)) make hydrophobic contacts with 
dibenzocycloheptene of (+)-butaclamol Cl.  
Ach, the natural agonist of Asu-ACR-16 was docked into the ligand binding 
sites of three forms of Asu-ACR-16 models for comparison. As expected, ach bound 
to the orthosteric binding site of the agonist-bound Asu-ACR-16 with an affinity (-4.3 
kcal/mol), which was higher than the affinities at the other binding sites. The binding 
pose of ach docked in the orthosteric binding site of the agonist-bound Asu-ACR-16 
model was in agreement with the binding pose of ach in the L. stagnalis AChBP 
cocrystal structure (PDB code: 3WIP; (Olsen et al., 2014b). The quaternary 
ammonium of ach faces to the basal side of the binding cavity and makes cation-π 
interaction with five aromatic residues from the Asu-ACR-16 ((+): Y89, W143, Y185, 
Y192; (-): W53), while the carbonyl oxygen of ach faces toward the apical side of the 
binding cavity. The binding affinities of the selected four compounds were higher 
than -8.0 kcal/mol in the three different bound forms of Asu-ACR-16, while the 
binding affinities of ach were lower than -4.5 kcal/mol in three states of Asu-ACR-16 
(Table 2). 
3.4 Pharmacological properties of virtual screening hits 
We tested the effects of the putative allosteric modulators on Asu-ACR-16 
receptors expressed in Xenopus oocyte using two-electrode voltage clamp to 
observe the currents that flow through Asu-ACR-16 receptors. Representative traces 
showing the inhibitory dose-response relationships are shown in Fig. 4. Their IC50 
(Fig. 5A & 5B) and maximum inhibition (Fig. S3) were determined as described in 
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the methods (Table 3). The most potent antagonist among them was SB-277011-A, 
which had an IC50 of 3.12 ± 1.29 µM and maximum inhibition effect of 96.07 ± 
10.66% (n = 4).  
The ach concentration-response plots in the presence of 3 µM of each 
putative allosteric modulator (Fig. S4 & 5C), show the reduced maximum current 
responses with little shift in EC50 of ach (Fig. 5D 5E & Table 4), and that the hits 
were non-competitive antagonists and negative allosteric modulators.  
At 10 µM, SB-277011-A, showed evidence of a mixed competitive and non-
competitive antagonism (Fig. S5), characterized by a reduced maximum current 
response and a right-shift in the EC50 of ach (Fig. 5D & 5E). Thus, 10 µM SB-
277011-A appears to act at more than one binding site which may include the 
orthosteric binding sites and additional allosteric binding sites.  
3.5 SB-277011-A reversibly inhibits locomotion in C. elegans 
We tested the effects of each allosteric modulator on the locomotion of C. 
elegans L4 larvae. The number of normal worms with thrashing-like movement 
dropped by 60% in 5 min after exposed to 30 µM SB-277011-A (p < 0.01, n = 5, t-
test). Paralysis-like movement was observed in the rest of the worms. The number 
of worms with normal motility recovered to 50% (p < 0.05, n = 5, t-test) in 10 min, 
85% in 15 min (p > 0.05, n = 5, t-test) and returned to near negative control values 
after 20 min (Fig. S6). The recovery may relate to the desensitization properties of 
the ACR-16 receptor. The reversible inhibition of motility in worms was also 
observed in 100 µM (+)-butaclamol Cl, but no significant difference between the 
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number of normal treated worms and negative control was observed at any time 
point. No visual effects of 100 µM fmoc-2 or 100 µM fmoc-1 were found on the 
locomotion of worms.    
4. Discussion 
4.1 Asu-ACR-16 models 
We have built up three-dimensional models of full-length structures of Asu-
ACR-16 at the atomic level for the first time. We used homology modeling based on 
X-ray crystal structures of human α7 nAChR chimeras and the electron microscopic 
structure of the T. marmorata nAChR as templates for different domains. The quality 
of our homology models are dependent on the sequence identity of the templates 
(human α7 nAChR chimeras and T. marmorata nAChR) and the target sequence 
(Asu-ACR-16) and the resolutions of template structures (Hillisch et al., 2004; 
Cavasotto et al., 2009). Our three ECD-Asu-ACR-16 models are likely to be reliable 
for virtual screening because they have high sequence identities (37.6% identity and 
72.9% similarity) with high resolution (< 4Å) templates. More errors might be 
expected in the TID-Asu-ACR-16 model, because of the missing loop between M3 
and MA in the template structure which reduces sequence identity with the target 
protein. The missing loop does not include an allosteric binding site. So we can 
assume that the TID-Tma-nAChR structure is similar to the TID-Asu-ACR-16 
structure (Bertrand et al., 2008). The overall secondary structures of our models are 
also consistent with published nAChRs structures (Finer-Moore et al., 1984; 
Miyazawa et al., 2003; Unwin, 2005b).       
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We developed the apo, the agonist-bound and the antagonist-bound models of the 
ECD-Asu-ACR-16 on the assumption that these three states of the Asu-ACR-16 
receptor most closely represent the receptor conformations in the presence and 
absence of agonists or antagonists. To produce a realistic dynamic model would 
require more extensive work (Cavasotto et al., 2007; Spyrakis et al., 2011) and is 
beyond the scope of this study. 
4.2 Virtual screening 
Our structure-based virtual screening approach identified four novel and 
potent negative allosteric modulators of Asu-ACR-16, which were validated by our 
electrophysiological studies. The putative ligands were initially selected based on the 
virtual screening using the orthosteric binding site of the receptor. It was possible 
that these ligands could have been agonists or competitive antagonists that bind 
within the orthosteric binding site. In contrast, the pharmacological characterization 
of the four virtual screening hits shows that they behave as negative allosteric 
modulators and bind to allosteric sites. This outcome may be due to the hydrophobic 
properties of the four compounds that impedes their interactions with the orthosteric 
site in the extracellular domain of the receptor. The high lipid solubility of these 
compounds increases their concentration in the membrane lipid phase, in the region 
of the transmembrane allosteric sites.  
The binding affinities calculated in the scoring function of AutoDock Vina 
software usually increase with the number of non-hydrogen atoms, which may be 
due to the neglect of desolvation in the scoring function (Kuntz et al., 1999; Shoichet 
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et al., 1999; Park et al., 2006). This leads to a bias of virtual screening methods 
towards big molecules which are more hydrophobic, concentrated in the lipid bilayer, 
and less likely to interact with the binding sites in the extracellular domains (Hopkins 
et al., 2004). It is also pointed out that the simplified force fields used to estimate the 
binding free energies are unable to evaluate the conformational entropies and other 
contributions to the free energies (Cosconati et al., 2010). Thus, the success rate of 
identifying bioactive hits (44%) would be enhanced if we are able to include these 
additional parameters into a scoring function for virtual screening.  Another 
approach, which we did not follow here, to enhance the success rate of identifying 
bio-active hits, is to use the known agonists or antagonists as scaffolds. This would 
facilitate the identification of low molecular-weight and more hydrophilic agonists or 
antagonists, and allow further study of the quantitative structure-activity relationships 
(Sun, 2008). 
4.3 Four negative allosteric modulators of Asu-ACR-16 
We evaluated the potency of inhibition for the four negative allosteric 
modulators in our electrophysiology studies on Xenopus oocytes: SB-277011-A (IC50 
3.12 ± 1.29 µM) < (+)-butaclamol Cl (IC50 9.85 ± 2.37 µM) ≈ fmoc-1 (IC50 10.00 ± 
1.38 µM) < fmoc-2 (IC50 16.67 ± 1.95 µM). This rank of inhibition agrees with the 
level of effects of the four modulators in the motility of C. elegans. The most potent 
modulator SB-277011-A was shown to decrease the motility of C. elegans larvae for 
a duration of about ten minutes, yet less effective on adult C. elegans. 
Desensitization of the ACR-16 or other nAChRs in C elegans body muscle may be a 
reason for the reduced effects of SB-277011-A on worms (Hernando et al., 2012). 
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Treating the acr-16-null mutant of C. elegans with SB-277011-A can help us to 
investigate the mode of action of SB-277011-A on C. elegans as genetic models to 
understand SB-277011-A action on the parasitic nematode A. suum (Ward, 2015).     
4.4 Allosteric binding sites may offer a better opportunity for drugs that can 
discriminate between the parasite Asu-ACR-16 and mammalian host α7 
nAChR 
Asu-ACR-16 shows 42.5% sequence identity and 71.2% sequence similarity 
with the human α7 nAChR (SwissProt ID: P36544) based on the alignment 
generated by CLUSTALW (Fig. S7, CLUSTALW job ID: cfed4f821eaf). The residues 
constituting the orthosteric binding site (pink and orange arrows in Fig. S7) are 
highly conserved between Asu-ACR-16 and human α7 nAChR, which shows 66.7% 
identity and 100% similarity (Fig. S8). In contrast, the residues of the four allosteric 
binding sites have much greater differences (variance) between the nematode 
parasite and the equivalent sites on the α7 receptor (identities: 62.5%, 45.5%, 
66.7%, 62.5% and 40.0% and; similarities: 87.5%, 81.8%, 83.3, 93.8% and 100%). 
The sequence divergence in the allosteric binding sites between Asu-ACR-16 and 
host human α7 nAChR indicates that drugs targeted at these sites may be more 
selective than drugs targeted at orthosteric binding sites. Virtual screening 
specifically targeting the allosteric binding sites is predicted to offer a better 
opportunity for development of drugs with much greater receptor subtype selectivity 
(Nussinov et al., 2013; Iturriaga-Vasquez et al., 2015).  
4.4 Conclusion 
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We have developed a structure-based in silico screening approach to search 
for the bioactive hits that target at a parasitic nematode receptor. This approach 
allowed us to identify four negative allosteric modulators that were validated using 
our electrophysiological studies. These four compounds may be useful leads for 
anthelminthic drug discovery. We point out however, that we have not yet made the 
structural models for the host human α7 nAChR or other receptors, which would help 
to distinguish compounds that are active only on the nematode receptors, thereby 
reducing potential toxicity. It would also be desirable to perform virtual screening for 
toxicity on a range of host receptors, some structures of which have already been 
determined and others need to be modeled. 
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Figure 1. (A) Sequence and numbering of the ECD-Asu-ACR-16 and its alignment 
with the template, human α7 nAChR chimera subunit. Completely conserved 
residues (red background) and partially conserved residues (yellow background) are 
indicated. Secondary structures are shown schematically above the sequences. α1 
represents α helix. β1-7 represent β strand. η1 represents 310 helix. The Cysteine loop 
and loop A - F are labeled by dark green bars. Residues in the orthosteric binding 
site are indicated by arrows (principal subunit, pink; complementary subunit, 
orange). Residues in three allosteric binding pockets are highlighted by arrows 
(principal subunit of agonist sub-pocket, turquoise; complementary subunit of 
agonist sub-pocket, green; principal subunit of vestibule pocket, dark green; 
complementary subunit of vestibule pocket, gold; principal subunit of top pocket, 
purple).   
(B) Sequence and numbering of the TID-Asu-ACR-16 and its alignment with the 
template TID-Tma-AChR subunit A. Completely conserved residues (red 
background) and partially conserved residues (yellow background) are indicated. 
Four transmembrane α helixes (M1, M2, M3 and M4) are shown schematically 
above the sequences. Residues in the allosteric binding pocket are indicated by 
arrows (principal subunit, pink; complementary subunit, orange).  
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Figure 2. (A) Ribbon diagram of the antagonist-bound model of ECD-Asu-ACR-16 
viewed from the synaptic cleft, showing the location of the orthosteric binding site 
and agonist sub-pocket. For clarity, only the front two subunits are highlighted 
(principal subunit, light pink; complementary subunit, yellow). The residues that 
contribute to the orthosteric binding site (principal side, pink; complementary side, 
orange) and the agonist sub-pocket (principal side, turquoise; complementary side, 
green) are represented by sticks and highlighted inside the red dotted circle. 
(B) Ribbon diagram of the antagonist-bound model of TID-Asu-ACR-16 viewed 
above the membrane, showing the location of two transmembrane allosteric binding 
sites. For clarity, only the front two subunits are highlighted (principal subunit, light 
pink; complementary subunit, yellow). The residues that contribute to the 
intersubunit site (principal side, pink; complementary side, orange) and intrasubunit 
site (principal side, purpleblue) are represented by sticks and highlighted inside the 
red dotted circle. 
(C) Ribbon diagram of the antagonist-bound model of full-length Asu-ACR-16 
viewed parallel to the membrane plane, showing the location of the orthosteric 
binding site and the agonist sub-pocket in the extracellular domain, the intersubunit 
and intrasubunit binding sites in the transmembrane domain. For clarity, only the 
front two subunits are highlighted (principal subunit, light pink; complementary 
subunit, yellow). The residues that contribute to the ligand binding sites are 
represented by sticks (orthosteric site: (+), pink; (-), orange; agonist sub-pocket: (+), 
turquoise; (-), green; intersubunit transmembrane site: (+), pink; (-), orange; 
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intrasubunit transmembrane site: purpleblue) and highlighted inside the red dotted 
circle. 
(D) Detailed view of the orthosteric binding site and agonist sub-pocket in the 
antagonist-bound model of ECD-Asu-ACR-16. The principal subunit is colored light 
pink, whereas the complementary subunit is colored yellow. The residues that 
contribute to the orthosteric binding site (principal side, pink; complementary side, 
orange) and the agonist sub-pocket (principal side, turquoise; complementary side, 
green) are represented by sticks and highlighted inside the red dotted circle. Carbon 
is in either turquoise or green. Nitrogen is in blue. Oxygen is in red.  
(E) Detailed view of the transmembrane allosteric binding sites in the antagonist-
bound model of TID-Asu-ACR-16. The principal subunit is colored light pink, 
whereas the complementary subunit is colored yellow. The residues that contribute 
to intersubunit site (principal side, pink; complementary side, orange) and 
intrasubunit site (principal side, purpleblue) are represented by sticks and 
highlighted inside the red dotted circle. Carbon is in either pink or orange or 
purpleblue. Nitrogen is in blue. Oxygen is in red. Sulfur is in yellow. 
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Figure 3. Binding modes of four virtual screening hits in the orthosteric binding site, 
the agonist sub-pocket, the intersubunit and intrasubunit transmembrane allosteric 
binding pockets of the antagonist-bound model of Asu-ACR-16: (A), (B), (C), (D) 
fomc-2; (E), (F), (G), (H) SB-277011-A; (I), (J), (K) fomc-1; (L), (M), (N), (O) (+)-
butaclamol Cl. Hits docked into the binding pockets are represented by sticks 
(carbon in yellow; ring in white; nitrogen in blue; oxygen in red). 
(A), (E), (I) and (L) show the four hits bound in the orthosteric binding site of the 
antagonist-bound model of ECD-Asu-ACR-16. The front two subunits are highlighted 
(principal subunit, light pink; complementary subunit, yellow). The residues in the 
orthosteric binding site are labeled (principal side, pink; complementary side, 
orange) to show the location of the orthosteric binding site. 
(B), (F), (J) and (M) show the four hits bound in the agonist sub-pocket of the 
antagonist-bound model of ECD-Asu-ACR-16. The front two subunits are 
highlighted. The residues in the agonist sub-pocket are labeled (principal side, 
turquoise; complementary side, green) to show the location of the agonist sub-
pocket. 
(C), (G) and (N) show the four hits bound in the intersubunit transmembrane site of 
the antagonist-bound model of TID-Asu-ACR-16. The front two subunits are 
highlighted. The residues in the intersubunit transmembrane site are labeled 
(principal side, pink; complementary side, orange) to show the location of the 
intersubunit transmembrane binding site.  
(D), (H), (K) and (O) show the four hits bound in the intrasubunit transmembrane site 
of the antagonist-bound model of TID-Asu-ACR-16. The residues in the intrasubunit 
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transmembrane site are labeled (purpleblue) to show the location of the intersubunit 
transmembrane binding site.
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Figure 4. Effects of four virtual screening hits on Asu-ACR-16 mediated ach 
responses. Sample traces for: (A) fmoc-2, (B) SB-277011, (C) (+)-butaclamol Cl, (D) 
fmoc-1 concentration-inhibition relationships on Asu-ACR-16. Mla in (D), which 
stands for methyllycaconitine citrate salt, was used as an antagonist control of Asu-
ACR-16. All four hits did not induce the current response by themselves, while 
produced the concentration-depended inhibition of ach current response. (E) is the 
magnified figure of part of (D) as an example to show the four parameters needed to 
measure the inhibition percentage. Imax control was the peak current of the control 30 
seconds application of 100 µM ach. Imax was the peak current of the 100 µM ach that 
preceded the 10 second co-application of ach and antagonist. Iant was the minimal 
current during the co-application of 100 µM ach and antagonist. Iant control was the 
current at the same point from the beginning of the 30 second application as Iant 
during the control 30 seconds application of 100 µM ach. 
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Figure 5. (A) Effects of four virtual screening hits on Asu-ACR-16 mediated ach 
responses. Fmoc-2, fmoc-1, (+)-butaclamol Cl and SB-277011-A concentration-
inhibition curves for Asu-ACR-16. Results were expressed as mean % inhibition of 
currents elicited by 100µM ach ± S.E.M.  
(B) Bar chart representing the IC50 (mean ± S.E.M, µM) of each plots in (A). The 
rank order series of inhibition based on IC50 for four hits is: SB-277011-A (3.12 ± 
1.29 µM, n = 4) < (+)-butaclamol Cl (9.85 ± 2.37 µM, n = 4) ≈ fmoc-1 (10.00 ± 1.38 
µM, n = 4) < fmoc-2 (16.67 ± 1.95 µM, n = 4). * represents p < 0.05 (unpaired t-test).  
(C) Ach concentration-response plots for Asu-ACR-16 in the absence of hits as a 
control (ach) and in the continual presence of four hits identified in (A). Ach 
concentration-response curves for Asu-ACR-16 in the presence of 3 µM of four hits: 
fmoc-1, fmoc-2, SB-27011-A and (+)-butaclamol Cl. 
(D) Bar chart (mean ± S.E.M, %) representing the reduced maximum current 
response of ach concentration-response curves in (C). The series of reduced 
maximum response of each hits compared to that of ach by unpaired t-test is: 10 µM 
SB-27011-A (5.51 ± 1.38%, n = 4), 3 µM (+)-butaclamol Cl (17.22 ± 1.94%, n = 4), 3 
µM SB-27011-A (23.25 ± 1.80%, n = 5), 3 µM fmoc-2 (49.92 ± 3.27%, n = 4), 3 µM 
fmoc-1 (61.25 ± 3.08%, n = 4) and ach (97.45 ± 1.19%, n = 4). * represents p < 0.05, 
** represents p < 0.01, *** represents p < 0.001. All four hits significantly inhibited 
the maximum current response induced by ach.    
(E) Bar chart (mean ± S.E.M, µM) displaying the EC50 of ach concentration-response 
curves in (C). The series of variable EC50 of each hits compared to that of ach by 
unpaired t-test is: 10 µM SB-27011-A (29.40 ± 2.27 µM, n = 4), 3 µM fmoc-1 (8.62 ± 
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1.04 µM, n = 4), 3 µM fmoc-2 (8.01 ± 0.18 µM, n = 4), 3 µM SB-27011-A (7.17 ± 0.33 
µM, n = 5), ach (5.92 ± 0.29 µM, n = 4) and 3 µM (+)-butaclamol Cl (3.94 ± 0.66 µM, 
n = 4). The EC50 of all four hits obviously shift away from the control when applied.   
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Tables 
Table 1. Physicochemical properties and chemical structures of four virtual screen 
hits. The four hits are: fmoc-4-(naphthalen-2-yl)-piperidine-4-carboxylic acid (fmoc-
2), SB-277011-A hydrochloride hydrate (SB-277011-A), fmoc-4-(naphthalen-1-yl)-
piperidine-4-carboxylic acid (fmoc-1), (+)-butaclamol hydrochloride ((+)-butaclamol 
Cl). The molecular mass (Mol. Mass), number of hydrogen bond donors, number of 
hydrogen bond acceptors, number of rotatable bonds and partition coefficient 
(xlogP) are listed for each hits.   
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Table 2. Binding affinities (kcal/mol) of the four hits and ach in the orthosteric 
binding sites of the three different bound models of ECD-Asu-ACR-16 and three 
allosteric binding sites of the antagonist-bound model of full-length Asu-ACR-16. 
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Table 3. Pharmacological profiles of the inhibitory effects of four hits on Asu-ACR-16 
mediated ach responses. Results (mean ± S.E.M.) were expressed as IC50 (µM), hill 
slope (nH), maximum inhibition (%) and the number of repeats (N) of each 
experiment. 
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Table 4. Pharmacological profiles of EC50 shifts and maximum current reductions of 
Asu-ACR-16 mediated ach responses in the presence and absence of four hits. 
Results (mean ± S.E.M.) were expressed as EC50 (µM), hill slope (nH) and maximum 
response (%) and the number of repeats (N) of each experiment. 
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Supplementary Data 
The following is the supplementary data related to this article: 
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Figure S1. (A) Ribbon representation of the ECD-Asu-ACR-16 monomer. 
Secondary elements are indicated. Loop A, B, C in the principal subunit and loop D, 
E, F in the complementary subunit which mainly contribute to the orthosteric binding 
site are labeled by dark green. In the complete structure, the C-terminal would enter 
the membrane at the bottom and link to M1 helix in the transmembrane domain. 
(B) Ribbon representation of the full-length Asu-ACR-16 monomer, as viewed 
parallel to the membrane plane. Four α helixes (M1, M2, M3 and M4) that contribute 
to transmembrane domain and one MA helix that makes up the intracellular domain 
are indicated. The functionally important M1-M2, M2-M3 and MA-M4 loops are 
labeled.  
(C) Superposition of antagonist-bound model of ECD-Asu-ACR-16 pentamer (purple 
blue) and template human α7 nAChR chimera (red; PDB code: 4HQP, ligands 
removed for clarity) viewed from the synaptic cleft. Five homomeric α-subunits are 
labeled. The interfaces between two vicinal α-subunits are marked by dotted lines. 
Five orthosteric binding sites are at each interface between the principal side (+) and 
the complementary side (-) from two vicinal subunits. 
(D) Superposition of TID-Asu-ACR-16 pentamer (purple blue) and template TID-
Tma-AChR (red; PDB code: 2BG9) viewed above the membrane. Five homomeric 
α-subunits are labeled. The interfaces between two vicinal α-subunits are marked by 
dotted lines. Five allosteric binding sites are at each interface among the M2, M3 in 
the principal side (+) and the M1 in the complementary side (-) from two vicinal 
subunits.          
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Figure S2. (A) Detailed view of the orthosteric binding site in the antagonist-bound 
model of ECD-Asu-ACR-16. Principal subunit is colored light pink, whereas the 
complementary subunit is colored yellow. The residues that contribute to the 
orthosteric binding site are represented by sticks (principal side (+), pink; 
complementary side (-), orange) and highlighted inside the red dotted circle. Carbon 
is in either pink or orange. Nitrogen is in blue. Oxygen is in red. Sulfur is in yellow.  
(B) Detailed view of the residues involving in the orthosteric binding site in the 
antagonist-bound model of ECD-Asu-ACR-16. Functionally important amino acids 
which interact with the ligands bound in this region are labeled. 
 (C) Detailed view of the agonist sub-pocket relative to the location of the orthosteric 
binding site in the antagonist-bound model of ECD-Asu-ACR-16. Principal subunit is 
colored light pink, whereas the complementary subunit is colored yellow. The 
residues that contribute to the agonist sub-pocket are represented by sticks 
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(principal side (+), turquoise; complementary side (-), green) and highlighted inside 
the red dotted circle at the bottom. Carbon is in either turquoise or green. Nitrogen is 
in blue. Oxygen is in red.  
(D) Detailed view of the residues involving in the agonist sub-pocket in the 
antagonist-bound model of ECD-Asu-ACR-16. Functionally important amino acids 
which interact with the allosteric modulators bound in this region are labeled. 
(E) Detailed view of the vestibule pocket relative to the location of the orthosteric 
binding site in the antagonist-bound model of ECD-Asu-ACR-16. Principal subunit is 
colored light pink, whereas the complementary subunit is colored yellow. The 
residues that contribute to the vestibule pocket are represented by sticks (principal 
side (+), dark green; complementary side (-), gold) and highlighted inside the red 
dotted circle on the left. Carbon is in either dark green or gold. Nitrogen is in blue. 
Oxygen is in red.  
(F) Detailed view of the residues involving in the vestibule pocket in the antagonist-
bound model of ECD-Asu-ACR-16. Functionally important amino acids which 
interact with the allosteric modulators bound in this region are labeled.  
(G) Detailed view of the top pocket relative to the location of the orthosteric binding 
site in the antagonist-bound model of ECD-Asu-ACR-16. Principal subunit is colored 
light pink, whereas the complementary subunit is colored yellow. The residues that 
contribute to the vestibule pocket are represented by sticks (principal side (+), 
purple) and highlighted inside the red dotted circle at the top. Carbon is in purple. 
Nitrogen is in blue. Oxygen is in red. 
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(H) Detailed view of the residues involving in the top pocket in the antagonist-bound 
model of ECD-Asu-ACR-16. Functionally important amino acids which interact with 
the allosteric modulators bound in this region are labeled.  
(I) Detailed view of the two transmembrane allosteric binding sites in the antagonist-
bound model of TID-Asu-ACR-16. Principal subunit is colored light pink, whereas the 
complementary subunit is colored yellow. The residues that contribute to the 
intersubunit site (principal side, pink; complementary side, orange) and intrasubunit 
site (principal side, purpleblue) are represented by sticks and highlighted inside the 
red dotted circle. Carbon is in either pink or orange or purpleblue. Nitrogen is in blue. 
Oxygen is in red. Sulfur is in yellow. 
(J) Detailed view of the residues involving in the two transmembrane allosteric 
binding sites in the antagonist-bound model of TID-Asu-ACR-16. Functionally 
important amino acids which interact with the allosteric modulators bound in this 
region are labeled. 
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Figure S3. Bar chart showing effects of the four hits on Asu-ACR-16. Results are 
expressed as maximum inhibition (mean ± S.E.M, %) of each plots in (Fig. 5A). The 
rank order series of inhibition based on maximum inhibition percentage for four hits 
is: SB-277011-A (96.07 ± 10.66%, n = 4) ≈ fmoc-1 (82.49 ± 4.74%, n = 4) ≈ fmoc-2 
(80.34 ± 10.32%, n = 4) ≈ (+)-butaclamol Cl (79.53 ± 12.41%, n = 4) using unpaired 
t-test. 
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Figure S4. Sample traces showing the effects of four hits on the acetylcholine 
concentration-response relationships for Asu-ACR-16. Sample trace of acetylcholine 
concentration-response relationships in the absence of hits is depicted in (A) as a 
control. 3 µM of each of four hits are applied: (B) fmoc-2, (D) SB-277011, (F) fmoc-1, 
(H) (+)-butaclamol Cl, to compare the EC50 shifts and the maximum response 
reduction for four hits. 1 µM SB-277011-A (C), 1 µM (+)-butaclamol Cl (G) and 10 
µM SB-277011-A (E) were tested to study the concentration effects on the mode of 
inhibition.
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Figure S5. Ach concentration-response curves for Asu-ACR-16 in the absence of 
hits as a control (ach) and in the continual presence of 1 µM, 3 µM, 10 µM SB-
277011-A, 1 µM, 3 µM (+)-butaclamol Cl.
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Figure S6. Plot of average number of L4 C. elegans larvae with normal motility (A) 
vs. time (min) in the absence of drug (1% DMSO, control), presence of 30 µM SB-
277011-A and 30 µM levamisole. Ten worms were used for each treatment, which 
was replicated by five times. Comparisons of locomotion were made between control 
and treated worms at each time point. * p < 0.05, ** p < 0.01, *** p < 0.001. The 
recovery of normal motility was observed only in the larvae treated with 30 µM SB-
277011-A within 20 minutes, but not in the larvae treated with 30 µM levamisole 
within 24 hours.    
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Figure S7. Sequence and numbering of the full-length Asu-ACR-16 and its 
alignment with the human α7 nAChR subunit. Completely conserved residues (red 
background) and partially conserved residues (yellow background) are indicated. 
Secondary structures are shown schematically above the sequences. α1 represents 
α helix. β1-7 represent β strand. η1 represents 310 helix. The Cysteine loop labeled by 
green bars. Four transmembrane α helixes (M1, M2, M3 and M4) are labeled by blue 
coils. Residues in the orthosteric binding site are indicated by arrows (principal 
subunit, pink; complementary subunit, orange). Residues in four allosteric binding 
sites are highlighted by arrows (principal subunit of agonist sub-pocket, turquoise; 
complementary subunit of agonist sub-pocket, green; principal subunit of vestibule 
pocket, dark green; complementary subunit of vestibule pocket, gold; principal 
subunit of top pocket, purple; principal subunit of intersubunit transmembrane site: 
bright pink; complementary subunit of intersubunit site: brown; principal subunit of 
intrasubunit site: purpleblue).  
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Figure S8. Comparison of residues in the orthosteric binding site and five allosteric 
binding sites between Asu-ACR-16 and human α7 nAChR.  
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16 ; (-) complementary side; ECD, extracellular domain; Lst-AChBP, Lymnaea 
stagnalis acetylcholine binding protein; nAChRs, nicotinic acetylcholine receptors; 
(+) principal side; 
Abstract 
The ACR-16 nicotinic acetylcholine receptor of Ascaris suum (Asu-ACR-16) is 
a homopentameric neurotransmitter-gated ion channel, which is widely distributed in 
A. suum tissues and plays an important role in the locomotion of worms. We chose 
Asu-ACR-16 as our pharmaceutical target and nicotine as our basic moiety to 
develop novel agonists of Asu-ACR-16. Our goal is to counteract the drug resistance 
which has occurred in the treatment of Ascaris infections. The structural models of 
the extracellular domains of Asu-ACR-16 was used to study the agonist-binding site 
and binding properties of potential agonists. We designed, synthesized and 
characterized the pharmacological profiles of several nicotine derivatives on Asu-
ACR-16 using Xenopus oocytes expression system and two-electrode voltage 
clamp. (S)-SIB 1508Y (EC50 0.37 ± 0.10 µM, Imax 100.01 ± 4.36 %) is significantly 
more potent and efficient than (S)-nicotine (EC50 6.21 ± 0.56 µM, Imax 82.39 ± 2.52 
%). 6-AN is a very potent non-competitive antagonist (IC50 2.00 ± 0.41 µM). These 
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data suggest that (S)-5-ethynyl-anabasine and several other nicotine alkaloids with 
high potencies and efficacies on Asu-ACR-16 may be promising leads for future 
anthelmintic drug development.  
 
Keywords: Asu-ACR-16, agonist-binding site, nicotine alkaloids, Xenopus 
expression, Ascaris suum, anthelmintic 
Introduction 
The nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated 
ion channels and involved in fast synaptic transmission in the central and peripheral 
nervous systems (Taly et al., 2009). The nAChRs can be activated by the 
neurotransmitter acetylcholine (ach), nicotine or its structurally related derivatives, 
which then lead to the opening of channel and a flux of sodium, potassium ions and 
sometimes calcium ions. 
The agonist-binding site of nAChRs was well studied by the combination of 
photolabeling, mutagenesis and electrophysiological approaches (Arias, 2000a). Our 
understanding of ligand-receptor interactions has improved via co-crystal structures 
of invertebrate acetylcholine binding proteins (AChBPs) with cholinergic ligands 
(Sixma et al., 2003; Rucktooa et al., 2009). AChBPs are homologs of the 
extracellular agonist-binding site domain of nAChRs and share 20–24 % sequence 
identity with the extracellular domain of AChRs (Blum et al., 2010). The agonist-
binding site of nAChRs is at the interface between principal subunit (with vicinal 
cysteines) and complementary subunit (without vicinal cysteines) in the extracellular 
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domain. Five aromatic amino acids in the agonist-binding site are highly conserved 
in nAChRs and contribute to the cation-π interaction with a characteristic cationic 
nitrogen in nAChR agonists (Dougherty, 2013). Another feature of nAChR agonists 
is the hydrogen bond acceptor, which is about 4-6 Å from the cationic nitrogen. 
Based on the high-resolution structures of AChBPs, the hydrogen bond acceptor in 
agonist is stabilized by a water molecule, which further interacts with carbonyl or 
amide backbones of two less conserved residues on loop E of the complementary 
subunit through three hydrogen bonding interactions (Van Arnam et al., 2014).  
Ascaris, a genus of clade III nematode parasites, are gastrointestinal 
roundworms that infect humans, pigs and other animals worldwide (Taylor et al., 
2016) and were estimated to cause more than 1.2 billion infections (de Silva et al., 
2003a). With no effective vaccines and inadequate sanitation in many countries, the 
control of Ascaris infection mainly relies on the limited number of available 
anthelmintic drugs. Unfortunately, drug resistances in various parasites have been 
reported due to the frequent use of anthelmintics (Garcia et al., 2016), which 
demand more potent and efficacious drugs for treatment.      
The ACR-16 nicotinic acetylcholine receptor of Ascaris suum (Asu-ACR-16) is 
a nematode homopentameric receptor, which closely resembles vertebrate α7 
nAChRs (Mongan et al., 2002). Asu-ACR-16 is widely distributed in A. suum tissues 
and may function in the motility of parasite. As one of the recently characterized 
nematode parasitic nAChRs, Asu-ACR-16 is pharmacologically different to its host 
α7 nAChR and has been exploited as an anthelmintic drug target to counter 
resistance (Holden-Dye et al., 2013; Zheng et al., 2016).  
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The agonist-binding site of the Asu-ACR-16 can be predicted by homology 
modeling using the human α7 nAChR chimera as structural template, which shares 
38% identity and 73% similarity in sequence. Five conserved aromatic residues and 
two hydrogen-bond interacting residues are in the close orientations with their 
corresponding residues in nAChRs, which therefore facilitates our further 
investigation of drug-receptor interactions on Asu-ACR-16 (Zheng et al., 2016).     
The Asu-ACR-16 is sensitive to six nicotinic agonists: nicotine, ach, cytisine, 
3-bromocytisine, epibatidine, dimethyl-4-phenyllpiperazinium iodide (DMPP), 
whereas insensitive to other cholinergic anthelmintic agonists (Abongwa et al., under 
review). All six Asu-ACR-16 agonists share the nicotinic pharmacophore: a cationic 
nitrogen separated certain distance from a hydrogen bond acceptor. Hence, we 
used a combination of structural modeling and synthetic strategy based on nicotinic 
pharmacophore to explore the pharmacological profiles of nicotine derivatives on 
Asu-ACR-16.   
Materials and Methods 
Materials 
Table 1 lists the chemicals used in electrophysiological studies. Acetylcholine 
chloride (ach), (-)-nicotine hydrogen tartrate salt ((S)-nicotine), anabasine ((S, R)-
anabasine), (±)-nornicotine (nornicotine), 5-(1-methyl-pyrrolidin-2-yl)-pyridin-2-
ylamine dihydrochloride (6-AN) and (-)-cotinine ((S)-cotinine), which were purchased 
from Sigma-Aldrich (St Louis, MO, USA). SIB 1508Y maleate (SIB 1508Y) was 
obtained from Tocris Bioscience (Ellisville, MO, USA). (S)-anabasine, rac-5-
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methylnicotine (5-methylnicotine), S-(-)-nicotine-5-carboxaldehyde ((S)-nicotine-5-
carboxaldehyde), (±)-6-methylnicotine (6-methylnicotine), (S)-1-methylnicotinium 
iodide ((S)-1-methylnicotinium), (S)-1’-methylnicotinium iodide ((S)-1’-
methylnicotinium), (R, S)-N-ethyl nornicotine (homonicotine), N-methyl anabasine 
were acquired from Toronto Research Chemicals (Toronto, ON, Canada).  
The following chemicals were used for the synthesis of (S)-5-bromonicotine, 
(S)-5-bromoanabsine and (S)-5-ethynyl-anabsine: 4, 4’-di-tert-butyl-2, 2’-dipyridyl, 
copper(II) bromide and 2-methyl-3-butyn-2-ol obtained from Sigma-Aldrich (St Louis, 
MO, USA); di-μ-methoxobis(1,5-cyclooctadiene)diiridium(I) and methanesulfonato(2-
di-t-butylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-
yl)palladium(II) obtained from Strem Chemicals (Newburyport, MA, USA); S-(-)-
nicotine and (-)-anabasine obtained from Alfa Aesar (Ward Hill, MA, USA); 
bis(pinacolato)diboron obtained from Matrix Scientific (Columbia, SC, USA); 
(trimethylsilyl)acetylene obtained from Oakwood Products (Estill, SC, USA).  
Synthesis of nicotine derivatives  
The reaction schemes for (S)-5-bromonicotine, (S)-5-bromoanabasine and 
(S)-5-ethynyl-anabasine were shown (Fig. 1) (Gros et al., 2006; Liskey et al., 2010). 
Given that this part of work was not contributed by me, and the synthetic and 
biological studies of (S)-5-ethynyl-anabasine have not been completed yet, all the 
work and result related to (S)-5-ethynyl-anabasine are to be added in this 
manuscript.   
Homology modeling and docking 
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The Asu-ACR-16 sequence is available in the UniProtKB with the accession 
number F1KYJ9 (Wang et al., 2011). Three crystal structures of human α7 nAChR 
chimera co-crystalized with ligands of different modes of action were used as 
templates to build three different bound-form models of the ECD-Asu-ACR-16 (Table 
2) (Li et al., 2011a; Huang et al., 2013; Zheng et al., 2016). The smiles strings of 
nicotine derivatives were obtained from the ZINC 
(http://zinc.docking.org/search/structure) and converted to PDBQT format. Docking 
of these ligands was performed in the orthosteric ligand-binding sites of agonist-
bound and apo form ECD-Asu-ACR-16 models using AutoDock Vina Software (Trott 
et al., 2010; Zheng et al., 2016).  
Expression and electrophysiology of Asu-ACR-16 in oocytes  
Full length Asu-acr-16 cRNA and ancillary gene Asu-ric-3 cRNA (UniProtKB 
accession number: F1L1D9) were prepared using the previous method (Zheng et al., 
2016). The cRNA mixture of 25 ng Asu-acr-16 and 5 ng Asu-ric-3 cRNA in 50 nL 
RNAse-free water was injected into the de-folliculated Xenopus laevis oocyte 
(Ecocyte Bioscience, Austin, TX, USA). The injected oocytes were incubated in the 
incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2·2H2O, 1 mM 
MgCl2·6H2O, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL penicillin, 100 μg/mL 
streptomycin, pH 7.5) at 19 °C for 4 – 8 days and added with 100 µM BAPTA-AM 3 h 
before recording.  
Two-electrode voltage-clamp was used to assay the electrophysiology of the 
Asu-ACR-16 expressed in oocytes. The oocytes were kept in the recording solution 
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(100 mM NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O and 5 mM HEPES, pH 7.3) and 
clamped at -60 mV during recording. Inward current signal in oocytes was induced 
by the addition of testing chemical each in the recording solution and measured by 
the two-electrode voltage-clamp (Molecular Devices, CA, USA). The data was 
acquired in Clampex 9.2 (Molecular Devices, CA, USA) and analyzed by GraphPad 
Prism 5.0 (Graphpad Software Inc., CA, USA).  
Pharmacological characterization of nicotinic derivatives and data analysis 
With the exception of ach, (S)-nicotine, SIB 1508Y, (S)-1-methylnicotinium, 
(S)-1’-methylnicotinium, nornicotine, (S)-cotinine, (S)-anabasine, (S,R)-anabasine 
which were dissolved in the recording solution, the rest of chemicals for 
electrophysiological studies were dissolved in DMSO to make 100 mM stock 
solutions of each. Recording solution was used to dilute the stock solutions and 
prepare a series of working solutions.  
100 µM ach was applied initially for 10 s as a control to check the Asu-ACR-
16 expression in all recordings and was used to normalize other current peak sizes. 
Recording solution was then used to wash out the drug from the oocytes for 3 min 
prior to next application of drug perfusion. 
To characterize the nicotine derivatives as agonists, increasing 
concentrations of the derivatives were applied for 10 s, with 3 min wash intervals to 
determine the dose-response relationship of each agonist. The dose-response 
relationships were described by the Hill equations to give estimates of the EC50 
(µM), Hill slope (nH), maximum response (Imax, %) and expressed as mean ± S.E.M. 
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(N = 5) by using GraphPad Prism 5.0 (Graphpad Software Inc., CA, USA). The EC50 
and Imax of each agonists were compared using the unpaired student t-test. P<0.05 
are used to evaluate the statistic difference.   
To determine the rank order potency of the nicotine derivatives as 
antagonists, 100 µM ach was applied for 10 s, followed by a 10 s co-application of 
100 µM nicotine derivative with 100 µM ach, and then a 10 s wash of 100 µM ach. 
The inhibition (%) of the 100 µM ach response was measured as described (Zheng 
et al., 2016), expressed as mean ± S.E.M. (N = 5) and compared using unpaired 
student t-test for the rank order of inhibition.                 
To characterize the antagonism of the selected nicotine derivative, increasing 
concentrations of the antagonist was applied using the previous procedure of 30 s 
co-application with 100 µM ach to determine the ach inhibitory dose-response 
relationship. The inhibitory dose-response relationship was fitted into the Hill 
equations to give estimates of the IC50 (µM), Hill slope (nH), maximum inhibition 
(Inhibitionmax, %) and expressed as mean ± S.E.M. (N = 5).  
To determine the effect of membrane potential on inhibition (%) of the 
selected antagonist, 3 µM antagonist was applied using the previous procedure of 
30 s co-application with 100 µM ach while holding the membrane potential at three 
different values to. (N = 5).  
To further study the antagonism, the selected antagonist was applied before 
and during 10 s application of increasing concentrations of ach. The ach dose-
response relationships in the presence of antagonist was fitted into the Hill equations 
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to estimate the EC50 (µM), Hill slope (nH), Imax (%) and expressed as mean ± S.E.M. 
(N = 5). 
Results 
Ligand-binding sites  
Lst-AChBP (PDB code: 1UW6) (Celie et al., 2004) showing 23.33% sequence 
identity and 64.29% sequence similarity with ECD-Asu-ACR-16 (Fig. S1A), is the 
only crystal structure of Asu-ACR-16 homologous protein co-crystalized with nicotine 
to date. The ligand-binding site for agonist is at the interface between the principal 
side (+) and the complementary side (-) in two adjacent subunits of nAChRs (Li et 
al., 2011a; Rucktooa et al., 2012).  
Nicotine adopted the same binding poses in all five ligand-binding sites in Lst-
AChBP pentamer (Fig. 2A). The pyrrolidine ring of nicotine is oriented toward the 
basal side of the binding site on the principal subunit, whereas the pyridine ring 
faces the apical side on the complementary subunit. The protonated N2 in 
pyrrolidine ring is involved in cation-π interaction with five aromatic side chains of 
residues in the binding site (principal subunit: Y89, W143, Y185, Y192; 
complementary subunit: W53). N2 is also hydrogen-bonded to the hydroxyl moiety of 
Y89 and W143 carbonyl backbone. Hydrophobic interactions from disulfide-bonded 
C187 and C188 on loop C stabilize nicotine in the binding site. The pyridine ring N1 
is hydrogen-bonded to a water molecule, which is stabilized by the carbonyl 
backbone of L102 and M114 amide backbone of the complementary subunit (Fig. 
2B) (Celie et al., 2004; Van Arnam et al., 2014). 
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Fig. 2C shows the ligand-binding site of the agonist-bound Asu-ACR-16 dimer 
viewed from the same angle as Fig. 2B. The residues involved in the binding site 
were highlighted in Fig. 2C and indicated in Fig. S1A by arrows. The interacting 
residues in the binding site of the agonist-bound Asu-ACR-16 model share similar 
orientations with those in the binding site of Lst-AChBP. The hydrophobic, hydrogen-
bond and van der Waals contacts between nicotine and AChBP were therefore 
predicted correspondingly in Asu-ACR-16. Y117, W173, Y214, Y221 from (+) and 
W79 from (-) constitute the aromatic cage which makes cation-π interaction with 
protonated tertiary amine or tetramethyl ammonium salt of nicotine or its derivatives. 
The hydroxyl moiety of Y117 and W173 carbonyl backbone are hydrogen-bonded to 
the protonated tertiary amine or ammonium of the ligand. The carbonyl backbone of 
N131 and I143 amide backbone from the complementary face have water-mediated 
hydrogen bond with the pyridine ring N1 of the ligand.  
Structural superimposition of the binding-site residues among three different 
bound forms Asu-ACR-16 showed the close-in conformational changes of residues 
when agonist is in complex, especially the inward movement of vicinal cysteines 
toward pyrrolidine N2 of nicotine. The antagonist-bound model has less steric 
hindrance in the open-up binding site (Fig. 2D) (Huang et al., 2013).      
The human α7 nAChR chimera (PDB code: 3SQ6) (Li et al., 2011a) shows 
62.98% sequence identity and 80.29% sequence similarity with the extracellular 
domain of human α7 nAChR (UniProtKB accession number: P36544). The residues 
constituting the ligand-binding site are highly conserved between human α7 nAChR 
chimera and human α7 nAChR (Fig. S1B). The crystal structure of human α7 
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nAChR chimera co-crystalized with epibatidine could be used to study the binding 
site of agonist-bound human α7 nAChR. Comparison of the binding sites in Lst-
AChBP (Fig. 3A), human α7 nAChR chimera (Fig. 3B), agonist-bound Asu-ACR-16 
(Fig. 3C) and apo form Asu-ACR-16 (Fig. 3D) reveals that 5-substituted pyridine 
derivatives of nicotine may be favorable to the binding site in the ECD-Asu-ACR-16, 
while disfavored by the human α7 nAChR sterically.  
Rank order of potency and efficiency for nicotine derivatives  
The EC50 and Imax for (S)-nicotine are 6.21 ± 0.56 µM and 82.39 ± 2.52 %, N = 
5 (Table 1). (S)-nicotine is a potent agonist of Asu-ACR-16, but can also activate 
mammalian nAChRs non-selectively and cause adverse side effects (Chavez-
Noriega et al., 1997). As a low-molecular-weight and water soluble molecule, (S)-
nicotine was selected as our initial lead for the further lead optimization (Bleicher et 
al., 2003). Using (S)-nicotine as a pharmacophore and the predicted three-
dimensional structures of Asu-ACR-16 ligand-binding site, we studied the structure-
activity relationship by characterizing the pharmacological properties of nicotine 
derivatives (Fig. 4) on Asu-ACR-16 (Fig. 5 & Fig. S2).  
Among the tested fifteen nicotine alkaloids, except for pyridine N1 methylated 
substituent: (S)-1-methylnicotium, 5’-carbonylated pyrrolidine substituent: (S)-
cotinine, and piperidine N2 methylated substituent: N-methyl anabasine do not show 
any intrinsic activities as agonists. The rest ten alkaloids act as agonists. The 
stimulatory dose-response relationships for ach and (S)-nicotine as controls (Fig. 
94 
 
6A), pyridine substituted nicotine derivatives (Fig. 6B) and the pyrrolidine substituted 
nicotine derivatives (Fig. 6C) were shown. 
The rank order of potency based on the EC50 values is: (S)-5-
bromoanabasine ≈ (S)-SIB 1508Y < 5-methylnicotine ≈ (S)-anabasine < (S)-5-
bromonicotine < 6-methylnicotine ≈ (S)-nicotine ≈ ach < (S)-1’-methylnicotinium ≈ 
(S)-nicotine-5-carboxaldehyde ≈ 6-AN < homonicotine ≈ nornicotine (Table 1). Two 
piperidine ring derivatives: (S)-5-bromoanabasine and (S)-anabasine, two 5-
substituted pyridine derivatives: (S)-SIB 1508Y and 5-methylnicotine are more 
potent than ach and (S)-nicotine (P<0.5, N = 5).  
The rank order of efficiency based on Imax is: (S)-SIB 1508Y ≈ ach ≈ (S)-1’-
methylnicotinium ≈ (S)-anabasine ≈ (S)-nicotine ≈ (S)-5-bromoanabasine ≈ 5-
methylnicotine > 6-methylnicotine ≈ (S)-5-bromonicotine ≈ nornicotine ≈ (S)-nicotine-
5-carboxaldehyde > homonicotine > 6-AN (Table 1). (S)-SIB 1508Y is more 
efficacious than (S)-nicotine (P<0.5, N = 5), whereas (S)-1’-methylnicotinium and 
(S)-anabasine are as efficacious as (S)-nicotine (P>0.5, N = 5). 
Inhibitory properties of nicotine derivatives  
The selected nicotine derivatives at 100 µM all illustrated the inhibitory effects 
on ach response for Asu-ACR-16 (Fig. S3). The rank order of inhibition based on the 
Inhibition (%) of 100 µM ach response is: 6-AN > homonicotine ≈ (S)-5-
bromonicotine ≈ 5-methylnicotine ≈ 6-methylnicotine ≈ (S)-nicotine-5-
carboxaldehyde ≈ (S)-SIB 1508Y ≈ N-methyl anabasine > (S)-1-methylnicotinium ≈ 
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(S)-nicotine ≈ (S)-anabasine ≈ nornicotine > (S)-1’-methylnicotinium > (S)-cotinine 
(Table 1).  
6-AN is the most potent inhibitor at 100 µM. Its IC50 is 2.00 ± 0.41 µM, nH is 
1.02 ± 0.05, inhibitionmax is 94.88 ± 1.49 % (N = 5) (Fig. 7A & S4A). The inhibition 
(%) of 6-AN on ach response is both concentration dependent and voltage 
dependent (Fig. 7B). The ach dose-response curves in the continual presence of 1 
µM 6-AN, showed the reduction in Imax with little shift of EC50 (Fig. 7C & 7D & S4B). 
Thus, 6-AN is a potent non-competitive antagonist of Asu-ACR-16.  
Enantiomers comparison  
We compared the pharmacological profiles of (S)-anabasine and its racemic 
mixture on Asu-ACR-16 (Fig. S5). The EC50 of (S)-anabasine is significantly lower 
than the EC50 of its racemic mixture (P<0.05, N = 5). The Imax of (S)-anabasine is 
slightly higher than that of its racemic mixture (P>0.05, N = 5). These results are 
consistent with other published results that illustrated the higher intrinsic activities on 
nAChRs in (S)-enantiomer nicotine alkaloids rather than their (R)-enantiomer 
(Cosford et al., 2000). Therefore, (S)-enantiomers of anabasine derivatives: (S)-5-
bromonicotine, (S)-5-bromoanabsine and (S)-5-ethynyl-anabsine were designed, 
synthesized and further tested in electrophysiology.  
Correlation between affinity and potency among nicotine derivatives 
The binding affinities of the selected nicotine derivatives were calculated by 
docking ligands into the agonist-binding site in the agonist-bound form, the apo form 
and the antagonist-bound form ECD-Asu-ACR-16 models respectively. We used 
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EC50 (µM) to evaluate the potency, Imax (%) to evaluate the efficacity, Inhibition (%) to 
evaluate the inhibitory effect of nicotine derivatives. The only correlation (positive) 
between the binding affinity and the potency toward the receptor was found in the 
apo form model (P < 0.05) (Fig. S6).  
Discussion 
Structure-activity relationships of nicotine derivatives 
Pyridine ring substituted derivatives To study the effects of functional 
groups added to the different positions of pyridine moiety on nicotine, methyl group 
as substituent at the 5- or 6- or N-pyridine moiety on nicotine or amino group at the 
6-pyridine moiety on nicotine are selected for the electrophysiology characterization. 
5-methylnicotine is the most potent and efficacious agonist, while 6-methylnicotine 
comes the second. 6-AN barely shows stimulatory activity, whereas behaves as a 
potent antagonist. The electron-donating group of methyl or amino at the 5- or 6-
pyridine increases the electronegativity and alkalinity of the pyridine N1, and so 
stabilizes the water-mediated hydrogen bond with the carbonyl backbone of N131 
and I143 amide backbone from the complementary subunit of the receptor. Instead, 
the lone pair electrons on the pyridine N1 of (S)-1-methylnicotinium are replaced by 
the methyl group. Thus, N1 cannot make hydrogen-bond with the carbonyl backbone 
of N131 and I143 amide backbone from the receptor, which inhibits the intrinsic 
activity of N-pyridine substituted derivatives. 
5-substituted pyridine derivatives Given that the electron-donating group 
substituting at the 5-pyridine of nicotine shows the highest activity as agonist, 
electron-withdrawing groups of acetylene, bromine or aldehyde at the 5-pyridine of 
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nicotine are then selected. (S)-SIB 1508 is the most potent and efficacious agonist, 
while (S)-5-bromonicotine and (S)-nicotine-5-carboxaldehyde come the second and 
third. Extra cavity is shown in the binding site of Asu-ACR-16 models for the linear 
acetylene substituent or globular bromine atom at the 5-pyridine moiety of nicotine to 
extend into. Instead, the bent structure of aldehyde may be less favored in the 
binding pocket.  
Pyrrolidine ring substituted derivatives To study the effects of functional 
groups added to the different positions of pyrrolidine moiety on nicotine, methyl or 
ethyl group as substituent at the N-pyrrolidine moiety on nicotine or ketone at the 5’-
pyrrolidine moiety on nicotine are selected for the electrophysiology characterization. 
The additional methyl group linked to the pyrrolidine N2 on (S)-1’-methylnicotinium 
makes it become quaternary ammonium, which increases its cation-π interaction 
with the five aromatic residues from the receptor, but also increases the steric 
hindrance around the pyrrolidine N2 and causes its stereochemically unfavorable. 
The increased steric hindrance due to the ethyl group at pyrrolidine N2 of 
homonicotine may be the reason of its reduced intrinsic activity. The secondary 
amine in nornicotine reduces its alkalinity and chance to make cation-π interaction 
with the receptor.     
Due to the conjugative effect of the lone pair electrons on pyrrolidine N2 of 
(S)-cotinine to the π bond of carbonyl group, the pyrrolidine N2 is hardly protonated 
and therefore inhibits the cation-π interaction with the aromatic cage from the 
receptor and cause the inactivity. 
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Piperidine ring derivatives The N-methyl pyrrolidine moiety was replaced by 
the N-methyl piperidine ring in nicotine structure to study the effect of increasing the 
membrane ring on the stimulatory activity of Asu-ACR-16. Yet, given that N-methyl 
anabasine is inactive, the piperidine moiety without methyl group was then studied 
and showed high intrinsic activity. The substituent piperidine of (S)-anabasine could 
sterically and electrostatically stabilize the aromatic cage on the receptor better than 
the N-methylated pyrrolidine ring of nicotine.  
Given that the electron-withdrawing substituent at the 5-pyridine of nicotine, 
such as (S)-SIB 1508Y, also shows high activity, we designed and synthesized the 
novel lead compound, (S)-5-ethynyl-anabasine, which is a combination of the 5-
ethynyl pyridine moiety from (S)-SIB 1508Y and the piperidine moiety from (S)-
anabasine structure.       
Open-channel block properties of nicotine derivatives 
The selected nicotine derivatives in high doses showed the tail current 
responses after the 10 s drug application (Fig. S2 & Fig. 5), which implied the ion 
channel switched from the open-blocked state to the open state. In addition, a 
voltage-sensitive inhibition (%) relationship was observed in a derivative with 
protonated N+. This property is consistent with the feature of open-channel blocker 
(Rossokhin et al., 2014).   
Both stimulatory effects and inhibitory effects were observed on several 
nicotine derivatives. 6-AN, a most potent Asu-ACR-16 inhibitor in our study, behaves 
as a non-competitive antagonist which bind to the site other than the orthosteric 
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ligand-binding site. Our electrophysiology results show 6-AN and other nicotine 
alkaloids are open-channel blockers of Asu-ACR-16. Since all these nicotine 
alkaloids have protonated tertiary amine or tetramethyl ammonium moiety, the 
cationic nitrogen of them not only makes cation-π interaction with the aromatic cage 
in the agonist-binding site of the receptor, but also acts as a cation that may interact 
with the channel pore and interfere with the channel gating. The ligands initially bind 
to the agonist-binding site and turn the channel from the rest state to the open state 
where the ions flow through the channel pore. As the channel is open, the extra 
ligands bind to the inside pore of channel and inhibit the current response, while 
preventing the dissociation of the initial ligand from the orthosteric site (Jackson, 
2010).   
Docking study as a probe for searching potent Asu-ACR-16 agonist   
The potency (EC50) of the selected nicotinic alkaloids is correlated most with 
the binding affinity in the apo model of Asu-ACR-16. This might be due to the 
movement of vicinal cysteines or the open-up orientation of W79 in the agonist-
bound and antagonist-bound form Asu-ACR-16, which reduces the cation-π 
interaction between W79 and nicotine N2 (Blum et al., 2010; Van Arnam et al., 
2014). The statistical correlation between the predicted ligand binding affinities in the 
apo model of Asu-ACR-16 and their corresponding potencies (EC50), suggests that 
the apo model may be reliable as a probe to search potent agonists by docking.     
Conclusion 
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We used the structural models of ECD-Asu-ACR-16 agonist-binding site and 
electrophysiology characterization of ion channel to study the structure-activity 
relationships of several nicotine alkaloids on Asu-ACR-16 receptor. We designed 
and synthesized (S)-5-etynyl-anabasine as our new lead compound, which was 
predicted to be more potent and efficacious than (S)-nicotine as a novel Asu-ACR-
16 agonist. Our structure-based drug discovery of ACR-16 agonists also proposed 
several other nicotine alkaloids as promising leads for further physicochemical and 
pharmacokinetic optimizations.  
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Figures 
 
Figure 1 Reaction schemes. 
Scheme 1 Reaction schemes of synthesizing (S)-5-bromoanabasine and (S)-5-
ethynyl-anabasine from (S)-anabasine 
Scheme 2 Reaction schemes of synthesizing (S)-5-bromonicotine from (S)-nicotine 
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Figure 2. Crystal structure of Lst-AChBP bound with nicotine (PDB code: 1UW6) 
and the agonist-bound model of Asu-ACR-16  
(A) Ribbon diagram of the AChBP co-crystalized with nicotine, as viewed with 
membrane at the bottom. The principal subunit is highlighted by light pink and the 
complement subunit is highlighted by light purple, for clarity. Nicotine (orange) is 
bound in the five ligand-binding sites in the extracellular domain of AChBP. 
(B) Close view of the AChBP ligand-binding site. The principal subunit in light pink, 
the complementary subunit in light purple. Residues interacting with nicotine 
(orange) are represented as sticks ((+), pink; (-), purple), and water molecule is 
shown as red dot, view with membrane at the bottom.  
(C) Close view of the agonist-bound model of Asu-ACR-16 ligand-binding site. The 
principal subunit in light pink, the complementary subunit in light purple. The 
interacting residues are represented as sticks ((+), pink; (-), purple), and water 
molecule is shown as red dot, view with membrane at the bottom.  
(D) Superposition of residues in agonist-binding site, among agonist-bound form 
(blue), apo form (yellow), antagonist-bound form (green) of Asu-ACR-16 models are 
shown.  
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Figure 3. Ligand-binding sites of Asu-ACR-16 and its homologous proteins  
(A) Surface representation in the open-up ligand-binding site of Lst-AChBP in 
complex with nicotine (PDB code: 1UW6). Oxygen-rich area (red), nitrogen-rich area 
(blue) and carbon-rich area (gray) are displayed. Empty space was observed around 
the 5-pyridine ring of nicotine, which suggests the ligand-binding site is in favor of 
the linear functional group linking toward the 5-pyridine ring of nicotine. Few space 
was found around the pyrrolidine ring of nicotine.       
(B) Surface representation in the open-up ligand-binding site of human α7 AChR 
chimera in complex with epibatidine (PDB code: 3SQ6), viewed by the same angle 
as (A). Oxygen-rich area (red), nitrogen-rich area (blue), carbon-rich area (pink) and 
chloride (green) are displayed. The azabicyclic ring N1 of epibatidine was 
superimposed with the pyrrolidine ring N2 of nicotine, while the pyridine ring N2 of 
epibatidine was superimposed with the pyridine ring N1 of nicotine.  
(C) Surface representation in the open-up ligand-binding site of agonist-bound Asu-
ACR-16 model, viewed by the same angle as (A). Oxygen-rich area (red), nitrogen-
rich area (blue) and carbon-rich area (cyan) are displayed. Assuming the nicotine 
has the same binding pose as in (A) within agonist-bound Asu-ACR-16, empty 
space is observed around the 5-pyridine ring and pyrrolidine ring of nicotine, which 
would make the nicotinic derivatives with modification in these positions favorable to 
the binding site.    
(D) Surface representation in the open-up ligand-binding site of apo form Asu-ACR-
16 model, viewed by the same angle as (A). Oxygen-rich area (red), nitrogen-rich 
area (blue) and carbon-rich area (yellow) are displayed. Assuming the nicotine has 
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the same binding pose as in (A) within apo form Asu-ACR-16, empty space is 
observed around the 5-pyridine ring and pyrrolidine ring of nicotine, which would 
make the nicotinic derivatives with modification in these positions favorable to the 
binding site.    
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Figure 4. Chemical structures of (S)-nicotine and its fifteen derivatives. 5-substituted 
pyridine ring derivatives: (S)-SIB 1508Y, (S)-5-bromonicotine, (S)-nicotine-5-
carboxaldehyde and 5-methylnicotine; other pyridine ring substituted derivatives: 
(S)-1-methylnicotinium, 6-methylnicotine and 5-(1-methyl-pyrrolidin-2-yl)-pyridin-2-
ylamine (6-AN); pyrrolidine ring substituted derivatives: (S)-1’-methylnicotinium, 
homonicotine, nornicotine and (S)-cotinine; piperidine ring derivatives: (S)-5-ethynyl-
anabasine, (S)-5-bromoanabasine, (S)-anabasine and N-methyl anabasine are 
shown.
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Figure 5. Sample traces for nicotine derivatives dose-response relationships of Asu-
ACR-16. (S)-5-bromoanabasine (A), (S)-SIB 1508Y (B), (S)-anabasine (C) are 
depicted.   
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Figure 6. Dose-response curves of nicotine derivatives for Asu-ACR-16. 
(A) Ach and (S)-nicotine as two controls.  
(B) Pyridine ring substituted derivatives. Responses of 30 µM 5-methylnicotine and 
100 µM 6-methylnicotine were shown but not fitted into their stimulatory dose-
response plots correspondingly due to their inhibitory effects. 
(C) Pyrrolidine ring substituted derivatives. Response of 300 µM homonicotine was 
shown but not fitted into its stimulatory dose-response plot due to its inhibitory effect.  
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Figure 7 Inhibitory effect of 6-AN on ach response for Asu-ACR-16. 
(A) 6-AN inhibitory dose-response relationship for Asu-ACR-16. One representative 
trace used to measure the inhibition (%) of 1 µM 6-AN on 100 µM ach response for 
Asu-ACR-16 was shown above the plot.    
(B) Voltage dependent-inhibition (%) of 3 µM 6-AN on 100 µM ach response for Asu-
ACR-16.    
(C) Ach dose-response relationships for Asu-ACR-16 in the absence of (black) and 
in the continual presence of 6-AN (blue), compared with 6-AN dose-response 
relationship (teal).  
(D) Bar chart comparing the EC50 (µM) and Imax (%) of ach dose-response 
relationships in the absence of (black) and in the presence of 6-AN (blue) by 
unpaired student-t test. ** P < 0.01. 
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Tables 
Table 1. Pharmacological profiles of ach and sixteen nicotine derivatives. Results 
(mean ± S.E.M.) were expressed as the EC50 (µM), Hill slope (nH) and maximum 
response (Imax, %), number of repeats of each agonist experiment (Nagonist), inhibition 
(%) and number of repeats of each inhibitor experiment (Ninhibitor). 
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Table 2. Structural information for the ECD-Asu-ACR-16 and two of its homologous 
proteins (human α7 nAChR chimera and Lst-AChBP).  
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Supplemental Data 
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Figure S1. Sequence alignment between Asu-ACR-16 and its homologous proteins  
(A) Sequence and numbering of the ECD-Asu-ACR-16 (SwissProt ID: F1KYJ9) and 
its alignment with the Lst-AChBP (SwissProt ID: P58154). Completely conserved 
residues (red) and partially conserved residues (yellow) were indicated. Residues in 
the ligand-binding site of the principal subunit (pink arrow) were highly conserved, 
while the residues in the ligand-binding site of the complementary subunit of (purple 
arrow) were variable between Asu-ACR-16 and Lst-AChBP subunit.  
(B) Sequence and numbering of the ECD of human α7 nAChR chimera (PDB code: 
3SQ6) and its alignment with the ECD of human α7 nAChR (SwissProt ID: P36544). 
Completely conserved residues (red) and partially conserved residues (yellow) were 
indicated. Residues in the ligand-binding site of the principal subunit (pink) and 
residues in the ligand-binding site of the complementary subunit (purple) were 
highlighted by arrows. Except T150 on (+) and L106 on (-) of human α7 nAChR 
chimera are different with S172 on (+) and N129 on (-) of human α7 nAChR, the rest 
of interacting residues in human α7 nAChR chimera and human α7 nAChR were 
identical.  
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Figure S2. Sample traces for nicotine derivatives concentration-response 
relationships of Asu-ACR-16.  
(S)-SIB 1508Y (A), 5-methylnicotine (B), (S)-5-bromonicotine (C), 6-methylnicotine 
(D), (S)-nicotine (E), ach (F), (S)-1’-methylnicotinium (G), (S)-nicotine-5-
carboxaldehyde (H), 6-AN (I), homonicotine (J), nornicotine (K) and (S, R)-
anabasine (L) are depicted. The characteristic tail current in (S)-SIB 1508 is labeled 
by green arrow in (A).    
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Figure S3 Sample traces showing the inhibitory effects of 100 µM nicotine 
derivatives on 100 µM ach response. 
(S)-cotinine, 6-AN, 6-methylnicotine and (S)-nicotine (A); homonicotine, 5-
methylnicotine and (S)-1’-methylnicotinium (B); (S)-anabasine and (S)-5-
bromonicotine (C); N-methylanabasine, (S)-1-methylnicotinium, nornicotine, (S)-
nicotine-5-carboxaldehyde and (S)-SIB 1508Y (D) and (S)-5-bromoanabasine and 
(S)-5-ethynyl-anabsine (E) inhibitory effects on ach response for Asu-ACR-16 are 
depicted. 
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Figure S4 Sample traces evaluating the potency and mechanism of 6-AN as an 
antagonist. 
(A) Sample trace showing the inhibitory dose-response relationship for Asu-ACR-16.  
(B) Sample trace showing the effects of 1 µM 6-AN on ach dose-response 
relationship for Asu-ACR-16. 
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Figure S5. Pharmacological profiles of (S)-anabasine and its racemic mixture. 
(A) Dose-response curves of (S)-anabasine (blue) and (S, R)-anabasine (dark 
yellow) for Asu-ACR-16. Response of 100 µM (S, R)-anabasine was shown but not 
fitted into its stimulatory dose-response plot due to its inhibitory effect.   
(B) Bar chart representing the EC50 and Imax (mean ± S.E.M, µM) of (S)-anabasine 
and its racemic mixture in (A). Significance was determined by un-paired student t-
test. (S)-anabasine (1.26 ± 0.19 µM, N = 5) < (S, R)-anabasine (2.03 ± 0.08 µM, N = 
5), ** P<0.01. (S)-anabasine (84.82 ± 4.20 %, N = 5) ≈ (S, R)-anabasine (79.56 ± 
2.24 %, N = 5), P>0.05. 
(C) Bar chart representing the Inhibition (mean ± S.E.M, %) of (S)-anabasine and its 
racemic mixture. Representative traces used to measure the inhibition (%) of 100 
µM (S)-anabasine or its racemic mixture on 100 µM ach response for Asu-ACR-16 
were shown above the chart. (S)-anabasine (28.44 ± 3.74 %, N = 5) ≈ (S, R)-
anabasine (41.98 ± 4.88 %, N = 5), P>0.05. 
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Figure S6. Correlations between binding affinities (kcal/mol) and EC50 (µM) (A), 
binding affinities (kcal/mol) and Imax (%) (B), binding affinities (kcal/mol) and 
Inhibition (%) (C), for the selected nicotine derivatives. The binding affinity of each 
derivative in the agonist-bound Asu-ACR-16 (blue), in the apo form Asu-ACR-16 
(yellow), in the antagonist-bound Asu-ACr-16 (green) and their correlation 
coefficients (r) were shown.  
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CHAPTER 4 
 GENERAL CONCLUSION AND FUTURE OUTLOOK 
The continual emergence of anthelmintic resistance in many animal species 
requires us to discover new lead compounds for anthelmintic drugs or to enhance 
the potency of existing anthelmintics. To achieve this goal, I used two different 
structure-based approaches: receptor-based drug design (Chapter 2) and ligand-
based drug design (Chapter 3) (Tollenaere).  
Receptor-based drug design relies on the structural and functional knowledge 
of a drug target. It is time-consuming and labor-intensive to resolve crystal structure 
of transmembrane receptor and to perform high-throughput drug screening. Advance 
in computational methods allows us to predict the receptor structure in atomic level 
and identify potential binding ligands from a large compound library, before investing 
in the experimental side.  
In Chapter 2, we made three-dimensional model of Asu-ACR-16, our drug 
target, and defined the ligand-binding sites based on other homologous co-crystal 
structures. Ligands from ZINC database were docked into these sites on Asu-ACR-
16 and each was output a binding affinity using the scoring functions. Those high-
affinity ligands were selected for further electrophysiology studies. TEVC was 
applied to characterize the pharmacological activities of ligands on the Asu-ACR-16 
receptor expressed in Xenopus oocytes. As an outcome, four out of nine ligands 
identified from virtual screening were validated to be negative allosteric modulators 
of Asu-ACR-16 and showed effects on worm locomotion.    
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The accuracy of virtual screening is mainly depended on the target structure 
and the scoring function that rank the interaction strengths between ligand and 
receptor. The predicted structure of receptor is based on the rigid crystal structure of 
homologous proteins, the conditions of which may not be the same as the protein in 
vivo. Thus, the conformation or folding of homologous proteins may be altered in the 
crystal structures ex vivo. In addition, it is insufficient to use static structures to mimic 
the dynamic nature of macromolecules, which as a result makes the predicted 
ligand-receptor interaction inaccurate (Sliwoski et al., 2014). Molecular dynamics 
simulations take multiple conformations of target receptor and solvent interactions 
into account and may serve as a solution (Nair et al., 2014). Another possible error 
may happen, when we use the ligand-binding site of homologous protein structure to 
predict ligand-binding site of target protein without site-direct mutagenesis. It largely 
limits our scopes to identify new binding sites on target receptor where potential 
ligands interact. Fragment-based lead discovery is an approach to link several weak-
binding fragments in discrete binding sites together into a high-affinity ligand. This 
approach is not heavily replied on the precise binding site localization, and thus may 
be more worthwhile to apply for future drug discovery (Erlanson et al., 2004).     
Ligand-based drug design relies on the analysis of ligands known to interact 
with the target receptor. The objective is to maintain the physicochemical properties 
that are essential for ligand-receptor interactions, while discard those not relevant to 
the interactions. In contrast to the receptor-based drug design, ligand-based drug 
design can also be applied when the structure of target receptor is unknown or 
unclear. It is also found that active compounds identified by ligand-based screening 
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methods are usually more potent than those identified by receptor-based screening 
methods (Stumpfe et al., 2012).  
In Chapter 3, we used nicotine, a potent but non-selective agonist of nAChRs, 
as our basic moiety/pharmacophore. We investigated the pharmacological 
properties of different substituents on nicotinic pharmacophore on Asu-ACR-16 
receptor. As a result, we found several 5-substituted pyridine derivatives of nicotine 
that show significantly higher potency and efficacity than nicotine on Asu-ACR-16 
receptor.  
Future work includes constructing quantitative structure-activity relationship 
(QSAR) models based on certain pharmacophore. The general idea of QSAR-based 
drug discovery is to develop mathematical descriptors that describe the 
physicochemical and structural properties of several structurally similar ligands. A 
QSAR model is developed to relate these descriptors with experimental/biological 
activity. QASR model can then be used to predict biological activity for a library of 
compounds using the same descriptors (Zhang, 2011). 
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